Thomas Kipps

Title(s)Professor, Medicine
SchoolVc-health Sciences-schools
Address9500 Gilman Drive #
La Jolla CA 92093
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Columbia College of Columbia University, New York, NYBS1974Biochemistry
    Harvard Medical School, Boston, MAPh.D.1979Immunology
    Collapse Awards and Honors
    UC San Diego School of Medicine2004Evelyn and Edwin Tasch Chair in Cancer Research

    Collapse Overview 
    Collapse Overview
    Thomas Kipps, MD, PhD, is Professor of Medicine, Evelyn and Edwin Tasch Chair in Cancer Research, and Deputy Director of Research Operations at the UC San Diego Moores Cancer Center. He received his Ph.D. in Immunology and M.D. from Harvard University and had his residency and fellowship training in Internal Medicine, Hematology, and Genetics at Stanford University.

    Dr. Kipps has a national and international reputation for his work in cancer research, immunology, and gene therapy. He has been a leader in the field for many years, and has helped to develop standardized treatment protocols. He is the author of more than 300 publications and is the PI on several peer-reviewed grants, including an award from NCI/NIH to fund the Chronic Lymphocytic Leukemia Research Consortium (CRC). The CRC involves collaboration with eight other Cancer Centers around the United States and the UK. Dr. Kipps is also the Director of the Blood Cancer Research Fund at the UC San Diego Moores Cancer Center. The Blood Cancer Research Fund concentrates on developing cures for all types of blood related cancers, specifically Chronic Lymphocytic Leukemia (CLL).

    Dr. Kipps has over 20 years’ experience in combining research and clinical care responsibilities. As deputy director of research operations, Dr. Kipps is working to further integrate basic and translational research investigators at the Moores Cancer Center with clinical investigators, epidemiologists, and physicians offering state-of-the art therapies for patients with various forms of cancer.

    Research Interests
    A major focus of Dr. Kipps’ research is the immunobiology and genetics of human B-cell malignancies, with emphasis on chronic lymphocytic leukemia (CLL). Dr. Kipps’ work has provided insight into the ontogeny of B cells that are subject to leukemia transformation and defined the highly restricted nature of the immunoglobulins expressed in this disease. In addition, he has defined genetic factors that contribute to the development and progression of this disease, identified biochemical pathways that enhance the growth or survival of leukemia B cells, identified means with which to elicit host anti-leukemia immune responses through vaccines generated via gene transfer, and identified promising new drugs and biologic agents that have activity in the treatment of this disease. He has made seminal observations on how the microenvironment can promote survival of CLL cells and defined strategies for mitigating the protective effects of the microenvironment on CLL cells survival in vivo. He has instigated and enabled work on selected leukemia cell samples of patients with sporadic or familial CLL that led to discovery of the role played by microRNA and ultraconserved, non-coding RNAs in the pathogenesis or progression of CLL in collaborations with the laboratory of Dr. Carlo Croce of the CLL Research Consortium (CRC). In other collaborations initiated through the CRC, Dr. Kipps also contributed to work on the epigenetic factors that contribute to pathogenesis in CLL.

    The study on CLL cells serially collected from patients at time points before therapy, during therapy, or after relapse from therapy allows for investigation of the genetic and biologic features associated with tumor progression, therapeutic response, or resistance to therapy. Discovery of features that distinguish CLL from their normal cell counterparts has helped identify new targets for therapy and/or define surrogate markers associated with more rapid rates of cancer progression or resistance to standard therapy. These studies are integrated with a clinical investigative program that attracts patients seeking improved modalities of treatment for CLL. From this, Dr. Kipps has identified molecular markers that can segregate patients into subgroups that have different risks for disease-progression or different probabilities of response to conventional treatment. This also has allowed for testing the safety and relative efficacy of novel agents developed for treatment of all patients with CLL or subgroups of patients hypothesized to have the best potential response to novel forms of therapy.

    Most recently, Dr. Kipps has discovered that the embryonic antigen ROR1 is expressed on CLL. ROR1 an embryonic type I membrane receptor tyrosine kinase-like surface protein. ROR1 was not expressed on normal, healthy adult tissues, but was found on the leukemia cells of virtually all cases of CLL and on the neoplastic cells of many patients with solid tumors. His work has demonstrated that patients immunized with autologous CLL cells transfected to express the CD40-ligand (CD154) can generate antibodies that are specific for this type I tyrosine kinase that apparently can block its capacity to function as a survival receptor for wnt5a. This work potentially could lead to development of novel vaccines for patients with this disease. Currently, Dr. Kipps is collaborating with other investigators at the UC San Diego Moores Cancer Center on developing monoclonal and recombinant antibodies specific for ROR1 and have identified one that can interfere with ROR1 signaling. The California Institute of Regenerative Medicine (CIRM) is funding this work.

    Another project undertaken in the Kipps’ lab is to define the nature of immunoglobulin gene expression in normal and neoplastic B cells and to examine the relationship between B-cell receptor signaling events and mechanisms governing the pathogenesis and/or progression of CLL. In addition he is investigating the role of the microenvironment in support both normal and neoplastic B cell survival. In addition to his laboratory research, Dr. Kipps is actively involved in clinical research; having developed and/or conducted several phase I and phase II clinical trials.

    Collapse Research 
    Collapse Research Activities and Funding
    Non-canonical Wnt-Receptor Signaling and Targeted Therapies
    NIH R01CA236361Apr 15, 2019 - Mar 31, 2024
    Role: Principal Investigator
    PCYC Karyotype
    Pharmacyclics, Inc. Jun 1, 2018 - Dec 31, 2021
    PCYC Clonal Evolution
    Pharmacyclics, Inc. Feb 21, 2018 - Feb 20, 2021
    Role: Principal Investigator
    A Phase 1b/2a Study of the ROR1-Targeting Monoclonal Antibody, Cirmtuzumab, and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in B-Cell Cancers
    California Institute for Regenerative Medicine (CIRM) CLIN2-10192Oct 1, 2017 - Jun 30, 2022
    Role: Principal Investigator
    Development of ROR1 CAR-T cells to target cancer stem cells in advanced malignancies
    California Institute for Regenerative Medicine (CIRM) TRAN1-10258Oct 1, 2017 - Mar 31, 2020
    Role: Co-Investigator
    Oncternal Research Agreement
    Oncternal Therapeutics, Inc. Sep 1, 2016 - Aug 31, 2021
    Role: Principal Investigator
    Oncternal Therapeutics, Inc. HRPP #140141Apr 1, 2016 - Sep 26, 2018
    Role: Principal Investigator
    ROR1 Expression in Human Breast Cancer
    Breast Cancer Research Foundation BCRF-18-123Oct 1, 2014 - Sep 30, 2019
    Role: Co-Investigator
    Protein-Coding and Non-Coding RNA Biomarkers for early detection of CLL
    MD Anderson Texas R01CA182905Jun 1, 2014 - May 31, 2019
    Role: Sub-Site Principal Investigator
    Cancer Center Support Grant (CCSG)
    NIH/NCI P30 CA23100-28May 1, 2014 - Apr 30, 2024
    Role: Senior Deputy Director, Co-Principal Investigator
    Specific Targets for Therapy of Patients with Chronic Lymphocytic Leukemia
    The Leukemia & Lymphoma Society 7005-14Oct 1, 2013 - Sep 30, 2018
    Role: Principal Investigator
    Chronic Lymphocytic Leukemia Research Consortium
    NIH/NCI 5P01CA081534-14Sep 24, 2012 - Aug 31, 2018
    Role: Principal Investigator
    Lenalidomide Treatment and the Chronic Lymphocytic Leukemia Microenvironment
    NIH R21CA135681Mar 1, 2009 - Feb 28, 2011
    Role: Principal Investigator
    Center of Nanotechnology for Treatment, Understanding, *
    NIH U54CA119335Sep 30, 2005 - Dec 31, 2011
    Role: Co-Investigator
    Chronic Lymphocytic Leukemia Research Consortium
    NIH P01CA081534May 1, 1999 - Aug 31, 2018
    Role: Principal Investigator
    CHRONIC LYMPHOCYTIC LEUKEMIA RESEARCH CONSORTIUM
    NIH P20CA081534May 1, 1999 - Apr 30, 2000
    Role: Principal Investigator
    MOLECULAR THERAPEUTICS OF RHEUMATOID ARTHRITIS
    NIH/NIAMS P50AR044850Sep 28, 1998 - Aug 31, 2004
    Role: Co-Investigator
    ERB 2NEU DNA VACCINES FOR BREAST CANCER IMMUNOTHERAPY
    NIH R01CA066000Sep 1, 1995 - Jun 30, 2003
    Role: Principal Investigator
    IMMUNOBIOLOGY OF AIDS LYMPHOMAS
    NIH R01CA065408Jul 25, 1994 - Jun 30, 1998
    Role: Principal Investigator
    NEW MODALITIES FOR ACTIVE IMMUNOTHERAPY OF MALIGNANCIES
    NIH R01CA057868Aug 25, 1992 - Jul 31, 1994
    Role: Principal Investigator
    NOVEL THERAPEUTIC APPROACHES IN HIV-ASSOCIATED LYMPHOMAS
    NIH R01CA055513Jul 16, 1991 - Jun 30, 1994
    Role: Principal Investigator
    MECHANISMS OF AIDS-ASSOCIATED LYMPHOMAGENESIS
    NIH R01CA054755Mar 14, 1991 - Feb 28, 1995
    Role: Principal Investigator
    Antibody V Gene Expression B Cell Lymphocytic Leukemia
    NIH R37CA049870May 1, 1989 - Jul 31, 2015
    Role: Principal Investigator
    ANTIBODY V GENE EXPRESSION IN HUMAN B CELL MALIGNANCIES
    NIH R01CA049870May 1, 1989 - Apr 30, 1994
    Role: Principal Investigator
    MULTIPARAMETER FLUORESCENCE ACTIVATED CELL SORTER
    NIH S10RR004051Apr 18, 1988 - Apr 17, 1990
    Role: Principal Investigator
    MULTIPURPOSE ARTHRITIS CENTER
    NIH P60AR033489Feb 1, 1987 - Jun 30, 1990
    Role: Co-Investigator
    HUMAN ANTIBODY DIVERSITY IN HEALTH &AUTOIMMUNITY
    NIH R29AR038475Aug 1, 1986 - Jul 31, 1992
    Role: Principal Investigator
    IMMUNOLOGIC AGING AND AUTOIMMUNITY
    NIH R01AG004100Jul 1, 1983 - Aug 31, 1996
    Role: Principal Investigator
    IMMUNOLOGIC AGING AND AUTOIMMUNITY
    NIH R55AG004100Jul 1, 1983 - Aug 31, 1992
    Role: Principal Investigator
    Specialized Cancer Center Support Grant
    NIH P30CA023100Apr 1, 1978 - Apr 30, 2024
    Role: Principal Investigator
    GENERAL CLINICAL RESEARCH CENTER
    NIH M01RR000833Dec 1, 1977 - Sep 30, 2005
    Role: Co-Investigator
    General Clinical Research Center
    NIH M01RR000827Mar 1, 1974 - Nov 30, 2010
    Role: Co-Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Impact of the Types and Relative Quantities of IGHV Gene Mutations in Predicting Prognosis of Patients With Chronic Lymphocytic Leukemia. Front Oncol. 2022; 12:897280. Kaufman M, Yan XJ, Li W, Ghia EM, Langerak AW, Rassenti LZ, Belessi C, Kay NE, Davi F, Byrd JC, Pospisilova S, Brown JR, Catherwood M, Davis Z, Oscier D, Montillo M, Trentin L, Rosenquist R, Ghia P, Barrientos JC, Kolitz JE, Allen SL, Rai KR, Stamatopoulos K, Kipps TJ, Neuberg D, Chiorazzi N. PMID: 35903706; PMCID: PMC9315922.
      View in: PubMed   Mentions:
    2. Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia. Blood Adv. 2022 06 14; 6(11):3440-3450. Barr PM, Owen C, Robak T, Tedeschi A, Bairey O, Burger JA, Hillmen P, Coutre SE, Dearden C, Grosicki S, McCarthy H, Li JY, Offner F, Moreno C, Zhou C, Hsu E, Szoke A, Kipps TJ, Ghia P. PMID: 35377947; PMCID: PMC9198904.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    3. Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort. Blood. 2022 06 02; 139(22):3278-3289. Tam CS, Allan JN, Siddiqi T, Kipps TJ, Jacobs R, Opat S, Barr PM, Tedeschi A, Trentin L, Bannerji R, Jackson S, Kuss BJ, Moreno C, Szafer-Glusman E, Russell K, Zhou C, Ninomoto J, Dean JP, Wierda WG, Ghia P. PMID: 35196370.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    4. NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022. J Natl Compr Canc Netw. 2022 06; 20(6):622-634. Wierda WG, Brown J, Abramson JS, Awan F, Bilgrami SF, Bociek G, Brander D, Chanan-Khan AA, Coutre SE, Davis RS, Eradat H, Fletcher CD, Gaballa S, Ghobadi A, Hamid MS, Hernandez-Ilizaliturri F, Hill B, Kaesberg P, Kamdar M, Kaplan LD, Khan N, Kipps TJ, Ma S, Mato A, Mosse C, Schuster S, Siddiqi T, Stephens DM, Ujjani C, Wagner-Johnston N, Woyach JA, Ye JC, Dwyer MA, Sundar H. PMID: 35714675.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    5. Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab. Blood. 2022 May 23. Seymour JF, Kipps TJ, Eichhorst B, D'Rozario J, Owen C, Assouline S, Lamanna N, Robak T, de la Serna J, Jaeger U, Cartron G, Montillo M, Mellink C, Chyla B, Panchal A, Lu T, Wu QJ, Jiang Y, Lefebure M, Boyer M, Kater AP. PMID: 35605176.
      View in: PubMed   Mentions:    Fields:    
    6. ROR1 - An Orphan Becomes Apparent. Blood. 2022 May 17. Kipps TJ. PMID: 35580162.
      View in: PubMed   Mentions:    Fields:    
    7. B-cell Receptor Signaling Induced Metabolic Alterations in Chronic Lymphocytic Leukemia Can Be Partially Bypassed by TP53 Abnormalities. Hemasphere. 2022 Jun; 6(6):e722. Kluckova K, Clear AJ, D'Avola A, Rassenti LZ, Kipps TJ, Gribben JG, Riches JC. PMID: 35747847; PMCID: PMC9208879.
      View in: PubMed   Mentions:
    8. High expression level of ROR1 and ROR1-signaling associates with venetoclax resistance in chronic lymphocytic leukemia. Leukemia. 2022 06; 36(6):1609-1618. Ghia EM, Rassenti LZ, Choi MY, Quijada-Álamo M, Chu E, Widhopf GF, Kipps TJ. PMID: 35418613; PMCID: PMC9162914.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    9. Single-cell analysis reveals immune dysfunction from the earliest stages of CLL that can be reversed by ibrutinib. Blood. 2022 04 07; 139(14):2252-2256. Purroy N, Tong YE, Lemvigh CK, Cieri N, Li S, Parry EM, Zhang W, Rassenti LZ, Kipps TJ, Slager SL, Kay NE, Lesnick C, Shanafelt TD, Ghia P, Scarfò L, Livak KJ, Kharchenko PV, Neuberg DS, Olsen LR, Fan J, Gohil SH, Wu CJ. PMID: 35020831; PMCID: PMC8990375.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    10. cyCombine allows for robust integration of single-cell cytometry datasets within and across technologies. Nat Commun. 2022 03 31; 13(1):1698. Pedersen CB, Dam SH, Barnkob MB, Leipold MD, Purroy N, Rassenti LZ, Kipps TJ, Nguyen J, Lederer JA, Gohil SH, Wu CJ, Olsen LR. PMID: 35361793; PMCID: PMC8971492.
      View in: PubMed   Mentions:    Fields:    
    11. Recent Advances in CAR T-Cell Therapy for Patients with Chronic Lymphocytic Leukemia. Cancers (Basel). 2022 Mar 28; 14(7). Heyman BM, Tzachanis D, Kipps TJ. PMID: 35406490; PMCID: PMC8996890.
      View in: PubMed   Mentions:
    12. Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL. Blood. 2022 03 24; 139(12):1794-1806. Siddiqi T, Soumerai JD, Dorritie KA, Stephens DM, Riedell PA, Arnason J, Kipps TJ, Gillenwater HH, Gong L, Yang L, Ogasawara K, Thorpe J, Wierda WG. PMID: 34699592.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    13. Modulation of RNA splicing associated with Wnt signaling pathway using FD-895 and pladienolide B. Aging (Albany NY). 2022 03 01; 14(5):2081-2100. Kumar D, Kashyap MK, Yu Z, Spaanderman I, Villa R, Kipps TJ, La Clair JJ, Burkart MD, Castro JE. PMID: 35230971; PMCID: PMC8954975.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    14. A large fraction of trisomy 12, 17p-, and 11q- CLL cases carry unidentified microdeletions of miR-15a/16-1. Proc Natl Acad Sci U S A. 2022 01 25; 119(4). Pepe F, Rassenti LZ, Pekarsky Y, Labanowska J, Nakamura T, Nigita G, Kipps TJ, Balatti V, Croce CM. PMID: 35064090; PMCID: PMC8794880.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    15. Ibrutinib plus Obinutuzumab as Frontline Therapy for Chronic Lymphocytic Leukemia Is Associated with a Lower Rate of Infusion-Related Reactions and with Sustained Remissions after Ibrutinib Discontinuation: A Single-Arm, Open-Label, Phase 1b/2 Clinical Trial NCT0231576. Adv Hematol. 2022; 2022:4450824. Castro JE, Lengerke-Diaz PA, Velez Lujan J, Choi MY, Moreno-Cortes EF, Forero JV, Garcia-Robledo JE, Jacobs C, McCarthy C, Heinen A, Amaya-Chanaga CI, Kipps TJ. PMID: 35103064; PMCID: PMC8800600.
      View in: PubMed   Mentions:
    16. Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies. Leuk Lymphoma. 2022 06; 63(6):1375-1386. Burger JA, Robak T, Demirkan F, Bairey O, Moreno C, Simpson D, Munir T, Stevens DA, Dai S, Cheung LWK, Kwei K, Lal I, Hsu E, Kipps TJ, Tedeschi A. PMID: 35014928.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    17. Longitudinal Single-Cell Dynamics of Chromatin Accessibility and Mitochondrial Mutations in Chronic Lymphocytic Leukemia Mirror Disease History. Cancer Discov. 2021 12 01; 11(12):3048-3063. Penter L, Gohil SH, Lareau C, Ludwig LS, Parry EM, Huang T, Li S, Zhang W, Livitz D, Leshchiner I, Parida L, Getz G, Rassenti LZ, Kipps TJ, Brown JR, Davids MS, Neuberg DS, Livak KJ, Sankaran VG, Wu CJ. PMID: 34112698; PMCID: PMC8660953.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    18. Activation of Notch and Myc Signaling via B-cell-Restricted Depletion of Dnmt3a Generates a Consistent Murine Model of Chronic Lymphocytic Leukemia. Cancer Res. 2021 12 15; 81(24):6117-6130. Biran A, Yin S, Kretzmer H, Ten Hacken E, Parvin S, Lucas F, Uduman M, Gutierrez C, Dangle N, Billington L, Regis FF, Rassenti LZ, Mohammad A, Hoffmann GB, Stevenson K, Zheng M, Witten E, Fernandes SM, Tausch E, Sun C, Stilgenbauer S, Brown JR, Kipps TJ, Aster JC, Gnirke A, Neuberg DS, Letai A, Wang L, Carrasco RD, Meissner A, Wu CJ. PMID: 34686499; PMCID: PMC8678341.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimalsCells
    19. Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study. J Clin Oncol. 2021 12 01; 39(34):3853-3865. Wierda WG, Allan JN, Siddiqi T, Kipps TJ, Opat S, Tedeschi A, Badoux XC, Kuss BJ, Jackson S, Moreno C, Jacobs R, Pagel JM, Flinn I, Pak Y, Zhou C, Szafer-Glusman E, Ninomoto J, Dean JP, James DF, Ghia P, Tam CS. PMID: 34618601; PMCID: PMC8713593.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    20. Efficacy of venetoclax plus rituximab for relapsed CLL: 5-year follow-up of continuous or limited- duration therapy. Blood. 2021 09 09; 138(10):836-846. Ma S, Seymour JF, Brander DM, Kipps TJ, Choi MY, Anderson MA, Humphrey K, Al Masud A, Pesko J, Nandam R, Salem AH, Chyla B, Arzt J, Jacobson A, Kim SY, Roberts AW. PMID: 34115103.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    21. Exploring the pathways to chronic lymphocytic leukemia. Blood. 2021 09 09; 138(10):827-835. Stevenson FK, Forconi F, Kipps TJ. PMID: 34075408; PMCID: PMC8432043.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimalsCells
    22. Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia. Haematologica. 2021 09 01; 106(9):2364-2373. Rogers KA, Thompson PA, Allan JN, Coleman M, Sharman JP, Cheson BD, Jones D, Izumi R, Frigault MM, Quah C, Raman RK, Patel P, Wang MH, Kipps TJ. PMID: 33730844; PMCID: PMC8409022.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    23. Polygenic risk score and risk of monoclonal B-cell lymphocytosis in caucasians and risk of chronic lymphocytic leukemia (CLL) in African Americans. Leukemia. 2022 01; 36(1):119-125. Kleinstern G, Weinberg JB, Parikh SA, Braggio E, Achenbach SJ, Robinson DP, Norman AD, Rabe KG, Boddicker NJ, Vachon CM, Lesnick CE, Call TG, Brander DM, Rassenti LZ, Kipps TJ, Olson JE, Cerhan JR, Kay NE, Furman RR, Hanson CA, Shanafelt TD, Slager SL. PMID: 34285341; PMCID: PMC8727288.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    24. Multifunctional barcoding with ClonMapper enables high-resolution study of clonal dynamics during tumor evolution and treatment. Nat Cancer. 2021 07; 2(7):758-772. Gutierrez C, Al'Khafaji AM, Brenner E, Johnson KE, Gohil SH, Lin Z, Knisbacher BA, Durrett RE, Li S, Parvin S, Biran A, Zhang W, Rassenti L, Kipps TJ, Livak KJ, Neuberg D, Letai A, Getz G, Wu CJ, Brock A. PMID: 34939038; PMCID: PMC8691751.
      View in: PubMed   Mentions: 7  Translation:HumansCells
    25. Mining the Microenvironment for Therapeutic Targets in Chronic Lymphocytic Leukemia. Cancer J. 2021 Jul-Aug 01; 27(4):306-313. Kipps TJ. PMID: 34398557.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    26. Long-term Follow-up of Patients with Relapsed or Refractory Non-Hodgkin Lymphoma Treated with Venetoclax in a Phase I, First-in-Human Study. Clin Cancer Res. 2021 09 01; 27(17):4690-4695. Davids MS, Roberts AW, Kenkre VP, Wierda WG, Kumar A, Kipps TJ, Boyer M, Salem AH, Pesko JC, Arzt JA, Mantas M, Kim SY, Seymour JF. PMID: 34083230.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    27. miR-29 modulates CD40 signaling in chronic lymphocytic leukemia by targeting TRAF4: an axis affected by BCR inhibitors. Blood. 2021 05 06; 137(18):2481-2494. Sharma S, Pavlasova GM, Seda V, Cerna KA, Vojackova E, Filip D, Ondrisova L, Sandova V, Kostalova L, Zeni PF, Borsky M, Oppelt J, Liskova K, Kren L, Janikova A, Pospisilova S, Fernandes SM, Shehata M, Rassenti LZ, Jaeger U, Doubek M, Davids MS, Brown JR, Mayer J, Kipps TJ, Mraz M. PMID: 33171493; PMCID: PMC7610744.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCells
    28. A hotspot mutation in transcription factor IKZF3 drives B cell neoplasia via transcriptional dysregulation. Cancer Cell. 2021 03 08; 39(3):380-393.e8. Lazarian G, Yin S, Ten Hacken E, Sewastianik T, Uduman M, Font-Tello A, Gohil SH, Li S, Kim E, Joyal H, Billington L, Witten E, Zheng M, Huang T, Severgnini M, Lefebvre V, Rassenti LZ, Gutierrez C, Georgopoulos K, Ott CJ, Wang L, Kipps TJ, Burger JA, Livak KJ, Neuberg DS, Baran-Marszak F, Cymbalista F, Carrasco RD, Wu CJ. PMID: 33689703; PMCID: PMC8034546.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimalsCells
    29. Impact of long-term ibrutinib treatment on circulating immune cells in previously untreated chronic lymphocytic leukemia. Leuk Res. 2021 03; 102:106520. Solman IG, Blum LK, Burger JA, Kipps TJ, Dean JP, James DF, Mongan A. PMID: 33611131.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCellsCTClinical Trials
    30. Recurrent XPO1 mutations alter pathogenesis of chronic lymphocytic leukemia. J Hematol Oncol. 2021 01 15; 14(1):17. Walker JS, Hing ZA, Harrington B, Baumhardt J, Ozer HG, Lehman A, Giacopelli B, Beaver L, Williams K, Skinner JN, Cempre CB, Sun Q, Shacham S, Stromberg BR, Summers MK, Abruzzo LV, Rassenti L, Kipps TJ, Parikh S, Kay NE, Rogers KA, Woyach JA, Coppola V, Chook YM, Oakes C, Byrd JC, Lapalombella R. PMID: 33451349; PMCID: PMC7809770.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimalsCells
    31. Preneoplastic Alterations Define CLL DNA Methylome and Persist through Disease Progression and Therapy. Blood Cancer Discov. 2021 01; 2(1):54-69. Kretzmer H, Biran A, Purroy N, Lemvigh CK, Clement K, Gruber M, Gu H, Rassenti L, Mohammad AW, Lesnick C, Slager SL, Braggio E, Shanafelt TD, Kay NE, Fernandes SM, Brown JR, Wang L, Li S, Livak KJ, Neuberg DS, Klages S, Timmermann B, Kipps TJ, Campo E, Gnirke A, Wu CJ, Meissner A. PMID: 33604581; PMCID: PMC7888194.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    32. Wnt5a enhances proliferation of chronic lymphocytic leukemia and ERK1/2 phosphorylation via a ROR1/DOCK2-dependent mechanism. Leukemia. 2021 06; 35(6):1621-1630. Hasan MK, Ghia EM, Rassenti LZ, Widhopf GF, Kipps TJ. PMID: 33097837; PMCID: PMC8062590.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    33. Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study. J Clin Oncol. 2020 12 01; 38(34):4042-4054. Kater AP, Wu JQ, Kipps T, Eichhorst B, Hillmen P, D'Rozario J, Assouline S, Owen C, Robak T, de la Serna J, Jaeger U, Cartron G, Montillo M, Dubois J, Eldering E, Mellink C, Van Der Kevie-Kersemaekers AM, Kim SY, Chyla B, Punnoose E, Bolen CR, Assaf ZJ, Jiang Y, Wang J, Lefebure M, Boyer M, Humphrey K, Seymour JF. PMID: 32986498; PMCID: PMC7768340.
      View in: PubMed   Mentions: 50     Fields:    Translation:HumansCTClinical Trials
    34. Distinct evolutionary paths in chronic lymphocytic leukemia during resistance to the graft-versus-leukemia effect. Sci Transl Med. 2020 09 16; 12(561). Bachireddy P, Ennis C, Nguyen VN, Gohil SH, Clement K, Shukla SA, Forman J, Barkas N, Freeman S, Bavli N, Elagina L, Leshchiner I, Mohammad AW, Mathewson ND, Keskin DB, Rassenti LZ, Kipps TJ, Brown JR, Getz G, Ho VT, Gnirke A, Neuberg D, Soiffer RJ, Ritz J, Alyea EP, Kharchenko PV, Wu CJ. PMID: 32938797; PMCID: PMC7829680.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    35. Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2020 09; 21(9):1188-1200. Al-Sawaf O, Zhang C, Tandon M, Sinha A, Fink AM, Robrecht S, Samoylova O, Liberati AM, Pinilla-Ibarz J, Opat S, Sivcheva L, Le Dû K, Fogliatto LM, Niemann CU, Weinkove R, Robinson S, Kipps TJ, Tausch E, Schary W, Ritgen M, Wendtner CM, Kreuzer KA, Eichhorst B, Stilgenbauer S, Hallek M, Fischer K. PMID: 32888452.
      View in: PubMed   Mentions: 47     Fields:    Translation:HumansCTClinical Trials
    36. Ibrutinib restores immune cell numbers and function in first-line and relapsed/refractory chronic lymphocytic leukemia. Leuk Res. 2020 10; 97:106432. Solman IG, Blum LK, Hoh HY, Kipps TJ, Burger JA, Barrientos JC, O'Brien S, Mulligan SP, Kay NE, Hillmen P, Byrd JC, Lal ID, Dean JP, Mongan A. PMID: 32911375.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCellsCTClinical Trials
    37. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 4.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2020 02; 18(2):185-217. Wierda WG, Byrd JC, Abramson JS, Bilgrami SF, Bociek G, Brander D, Brown J, Chanan-Khan AA, Chavez JC, Coutre SE, Davis RS, Fletcher CD, Hill B, Kahl BS, Kamdar M, Kaplan LD, Khan N, Kipps TJ, Lim MS, Ma S, Malek S, Mato A, Mosse C, Shadman M, Siddiqi T, Stephens D, Sundaram S, Wagner N, Dwyer M, Sundar H. PMID: 32023533.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCells
    38. Aurora B induces epithelial-mesenchymal transition by stabilizing Snail1 to promote basal-like breast cancer metastasis. Oncogene. 2020 03; 39(12):2550-2567. Zhang J, Lin X, Wu L, Huang JJ, Jiang WQ, Kipps TJ, Zhang S. PMID: 31996785.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimalsCells
    39. NF-κB-p62-NRF2 survival signaling is associated with high ROR1 expression in chronic lymphocytic leukemia. Cell Death Differ. 2020 07; 27(7):2206-2216. Sanchez-Lopez E, Ghia EM, Antonucci L, Sharma N, Rassenti LZ, Xu J, Sun B, Kipps TJ, Karin M. PMID: 31992855; PMCID: PMC7308363.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCells
    40. Genetic dynamics in untreated CLL patients with either stable or progressive disease: a longitudinal study. J Hematol Oncol. 2019 11 19; 12(1):114. Ramassone A, D'Argenio A, Veronese A, Basti A, Soliman SHA, Volinia S, Bassi C, Pagotto S, Ferracin M, Lupini L, Saccenti E, Balatti V, Pepe F, Rassenti LZ, Innocenti I, Autore F, Marzetti L, Mariani-Costantini R, Kipps TJ, Negrini M, Laurenti L, Visone R. PMID: 31744508; PMCID: PMC6862808.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    41. Dysregulation of different classes of tRNA fragments in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2019 11 26; 116(48):24252-24258. Veneziano D, Tomasello L, Balatti V, Palamarchuk A, Rassenti LZ, Kipps TJ, Pekarsky Y, Croce CM. PMID: 31723042; PMCID: PMC6883801.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCells
    42. Targeted Therapy in Chronic Lymphocytic Leukemia. Cancer J. 2019 Nov/Dec; 25(6):378-385. Kipps TJ, Choi MY. PMID: 31764118; PMCID: PMC7039327.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCells
    43. Wnt5a induces ROR1 to recruit cortactin to promote breast-cancer migration and metastasis. NPJ Breast Cancer. 2019; 5:35. Hasan MK, Widhopf GF, Zhang S, Lam SM, Shen Z, Briggs SP, Parker BA, Kipps TJ. PMID: 31667337; PMCID: PMC6814774.
      View in: PubMed   Mentions: 7  
    44. Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. Leukemia. 2020 03; 34(3):787-798. Burger JA, Barr PM, Robak T, Owen C, Ghia P, Tedeschi A, Bairey O, Hillmen P, Coutre SE, Devereux S, Grosicki S, McCarthy H, Simpson D, Offner F, Moreno C, Dai S, Lal I, Dean JP, Kipps TJ. PMID: 31628428; PMCID: PMC7214263.
      View in: PubMed   Mentions: 97     Fields:    Translation:HumansCTClinical Trials
    45. Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Am J Hematol. 2019 12; 94(12):1353-1363. Munir T, Brown JR, O'Brien S, Barrientos JC, Barr PM, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Kipps TJ, Moreno C, Montillo M, Burger JA, Byrd JC, Hillmen P, Dai S, Szoke A, Dean JP, Woyach JA. PMID: 31512258; PMCID: PMC6899718.
      View in: PubMed   Mentions: 74     Fields:    Translation:HumansCTClinical Trials
    46. Plasma B-Cell Maturation Antigen Levels are Elevated and Correlate with Disease Activity in Patients with Chronic Lymphocytic Leukemia. Target Oncol. 2019 10; 14(5):551-561. Udd KA, Bujarski S, Wirtschafter E, Spektor TM, Ghermezi M, Rassenti LZ, David ME, Nosrati JD, Rahbari AA, Wang J, Vardanyan S, Harutyunyan NM, Linesch J, Li M, Sanchez E, Chen H, Kipps TJ, Berenson JR. PMID: 31473933.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    47. A cross-trial comparison of single-agent ibrutinib versus chlorambucil-obinutuzumab in previously untreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. Haematologica. 2020 04; 105(4):e164-e168. Tedeschi A, Greil R, Demirkan F, Robak T, Moreno C, Barr PM, Anz B, Simpson D, Gaidano G, Bairey O, Stevens D, Gill D, Flinn IW, Kipps TJ, Burger JA, Lin J, Webb T, Fedorov V, Styles L, Gribben JG. PMID: 31413095; PMCID: PMC7109731.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    48. Cirmtuzumab blocks Wnt5a/ROR1 stimulation of NF-κB to repress autocrine STAT3 activation in chronic lymphocytic leukemia. Blood. 2019 09 26; 134(13):1084-1094. Chen Y, Chen L, Yu J, Ghia EM, Choi MY, Zhang L, Zhang S, Sanchez-Lopez E, Widhopf GF, Messer K, Rassenti LZ, Jamieson C, Kipps TJ. PMID: 31409670; PMCID: PMC6764264.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCells
    49. A multicenter phase 1 study of plerixafor and rituximab in patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2019 12; 60(14):3461-3469. Andritsos LA, Byrd JC, Cheverton P, Wu J, Sivina M, Kipps TJ, Burger JA. PMID: 31352850.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    50. Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia. Clin Lymphoma Myeloma Leuk. 2019 11; 19(11):715-722.e6. Kipps TJ, Fraser G, Coutre SE, Brown JR, Barrientos JC, Barr PM, Byrd JC, O'Brien SM, Dilhuydy MS, Hillmen P, Jaeger U, Moreno C, Cramer P, Stilgenbauer S, Chanan-Khan AA, Mahler M, Salman M, Eckert K, Solman IG, Balasubramanian S, Cheng M, Londhe A, Ninomoto J, Howes A, James DF, Hallek M. PMID: 31447270.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCells
    51. Developmental subtypes assessed by DNA methylation-iPLEX forecast the natural history of chronic lymphocytic leukemia. Blood. 2019 08 22; 134(8):688-698. Giacopelli B, Zhao Q, Ruppert AS, Agyeman A, Weigel C, Wu YZ, Gerber MM, Rabe KG, Larson MC, Lu J, Blachly JS, Rogers KA, Wierda WG, Brown JR, Rai KR, Keating M, Rassenti LZ, Kipps TJ, Zenz T, Shanafelt TD, Kay NE, Abruzzo LV, Coombes KR, Woyach JA, Byrd JC, Oakes CC. PMID: 31292113; PMCID: PMC6706807.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    52. Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies. Blood Adv. 2019 06 25; 3(12):1799-1807. Coutre SE, Byrd JC, Hillmen P, Barrientos JC, Barr PM, Devereux S, Robak T, Kipps TJ, Schuh A, Moreno C, Furman RR, Burger JA, O'Dwyer M, Ghia P, Valentino R, Chang S, Dean JP, James DF, O'Brien SM. PMID: 31196847; PMCID: PMC6595265.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansCTClinical Trials
    53. Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions. N Engl J Med. 2019 Jun 06; 380(23):2225-2236. Fischer K, Al-Sawaf O, Bahlo J, Fink AM, Tandon M, Dixon M, Robrecht S, Warburton S, Humphrey K, Samoylova O, Liberati AM, Pinilla-Ibarz J, Opat S, Sivcheva L, Le Dû K, Fogliatto LM, Niemann CU, Weinkove R, Robinson S, Kipps TJ, Boettcher S, Tausch E, Humerickhouse R, Eichhorst B, Wendtner CM, Langerak AW, Kreuzer KA, Ritgen M, Goede V, Stilgenbauer S, Mobasher M, Hallek M. PMID: 31166681.
      View in: PubMed   Mentions: 179     Fields:    Translation:Humans
    54. SOHO State of the Art Updates and Next Questions: The Conundrum in Assessing the Therapy Response of Patients With Chronic Lymphocytic Leukemia. Clin Lymphoma Myeloma Leuk. 2019 06; 19(6):321-325. Choi MY, Wang HY, Kipps TJ. PMID: 31204237.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    55. Growth dynamics in naturally progressing chronic lymphocytic leukaemia. Nature. 2019 06; 570(7762):474-479. Gruber M, Bozic I, Leshchiner I, Livitz D, Stevenson K, Rassenti L, Rosebrock D, Taylor-Weiner A, Olive O, Goyetche R, Fernandes SM, Sun J, Stewart C, Wong A, Cibulskis C, Zhang W, Reiter JG, Gerold JM, Gribben JG, Rai KR, Keating MJ, Brown JR, Neuberg D, Kipps TJ, Nowak MA, Getz G, Wu CJ. PMID: 31142838; PMCID: PMC6630176.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansCells
    56. Ibrutinib reduces obinutuzumab infusion-related reactions in patients with chronic lymphocytic leukemia and is associated with changes in plasma cytokine levels. Haematologica. 2020 01; 105(1):e22-e25. Lujan JV, Lengerke-Diaz PA, Jacobs C, Moreno-Cortes EF, Ramirez-Segura CA, Choi MY, McCarthy C, Heinen A, Kipps TJ, Castro JE. PMID: 31048356; PMCID: PMC6939526.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    57. Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables. Blood. 2019 07 11; 134(2):111-122. Roberts AW, Ma S, Kipps TJ, Coutre SE, Davids MS, Eichhorst B, Hallek M, Byrd JC, Humphrey K, Zhou L, Chyla B, Nielsen J, Potluri J, Kim SY, Verdugo M, Stilgenbauer S, Wierda WG, Seymour JF. PMID: 31023700; PMCID: PMC6624969.
      View in: PubMed   Mentions: 61     Fields:    Translation:HumansCTClinical Trials
    58. HNRNPL Restrains miR-155 Targeting of BUB1 to Stabilize Aberrant Karyotypes of Transformed Cells in Chronic Lymphocytic Leukemia. Cancers (Basel). 2019 Apr 23; 11(4). Pagotto S, Veronese A, Soranno A, Balatti V, Ramassone A, Guanciali-Franchi PE, Palka G, Innocenti I, Autore F, Rassenti LZ, Kipps TJ, Mariani-Costantini R, Laurenti L, Croce CM, Visone R. PMID: 31018621; PMCID: PMC6520824.
      View in: PubMed   Mentions: 3  
    59. Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia. J Clin Oncol. 2019 06 01; 37(16):1391-1402. Sharman JP, Coutre SE, Furman RR, Cheson BD, Pagel JM, Hillmen P, Barrientos JC, Zelenetz AD, Kipps TJ, Flinn IW, Ghia P, Eradat H, Ervin T, Lamanna N, Coiffier B, Pettitt AR, Ma S, Tausch E, Cramer P, Huang J, Mitra S, Hallek M, O'Brien SM, Stilgenbauer S. PMID: 30995176.
      View in: PubMed   Mentions: 52     Fields:    Translation:HumansCTClinical Trials
    60. Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemia. Blood Adv. 2019 04 09; 3(7):1167-1174. Lampson BL, Kim HT, Davids MS, Abramson JS, Freedman AS, Jacobson CA, Armand PA, Joyce RM, Arnason JE, Rassenti LZ, Kipps TJ, Fein J, Fernandes SM, Hanna JR, Fisher DC, Brown JR. PMID: 30967392; PMCID: PMC6457234.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    61. Activation of hedgehog signaling associates with early disease progression in chronic lymphocytic leukemia. Blood. 2019 06 20; 133(25):2651-2663. Ghia EM, Rassenti LZ, Neuberg DS, Blanco A, Yousif F, Smith EN, McPherson JD, Hudson TJ, HALT Pan-Leukemia Gene Panel Consortium, Harismendy O, Frazer KA, Kipps TJ. PMID: 30923040; PMCID: PMC6587306.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    62. Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia. Blood. 2019 06 27; 133(26):2765-2775. Flinn IW, Gribben JG, Dyer MJS, Wierda W, Maris MB, Furman RR, Hillmen P, Rogers KA, Iyer SP, Quillet-Mary A, Ysebaert L, Walter HS, Verdugo M, Klein C, Huang H, Jiang Y, Lozanski G, Pignataro DS, Humphrey K, Mobasher M, Kipps TJ. PMID: 30862645; PMCID: PMC6706803.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCTClinical Trials
    63. Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis. Am J Hematol. 2019 05; 94(5):554-562. O'Brien SM, Byrd JC, Hillmen P, Coutre S, Brown JR, Barr PM, Barrientos JC, Devereux S, Robak T, Reddy NM, Kipps TJ, Tedeschi A, Cymbalista F, Ghia P, Chang S, Ninomoto J, James DF, Burger JA. PMID: 30767298; PMCID: PMC6593416.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    64. Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab. Blood. 2019 05 09; 133(19):2031-2042. Byrd JC, Hillmen P, O'Brien S, Barrientos JC, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Barr PM, Furman RR, Kipps TJ, Thornton P, Moreno C, Montillo M, Pagel JM, Burger JA, Woyach JA, Dai S, Vezan R, James DF, Brown JR. PMID: 30842083; PMCID: PMC6509542.
      View in: PubMed   Mentions: 56     Fields:    Translation:HumansCTClinical Trials
    65. Tumour debulking and reduction in predicted risk of tumour lysis syndrome with single-agent ibrutinib in patients with chronic lymphocytic leukaemia. Br J Haematol. 2019 07; 186(1):184-188. Wierda WG, Byrd JC, O'Brien S, Coutre S, Barr PM, Furman RR, Kipps TJ, Burger JA, Stevens DA, Sharman J, Ghia P, Flinn IW, Zhou C, Ninomoto J, James DF, Tam CS. PMID: 30740654.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    66. A Murine Model of Chronic Lymphocytic Leukemia Based on B Cell-Restricted Expression of Sf3b1 Mutation and Atm Deletion. Cancer Cell. 2019 02 11; 35(2):283-296.e5. Yin S, Gambe RG, Sun J, Martinez AZ, Cartun ZJ, Regis FFD, Wan Y, Fan J, Brooks AN, Herman SEM, Ten Hacken E, Taylor-Weiner A, Rassenti LZ, Ghia EM, Kipps TJ, Obeng EA, Cibulskis CL, Neuberg D, Campagna DR, Fleming MD, Ebert BL, Wiestner A, Leshchiner I, DeCaprio JA, Getz G, Reed R, Carrasco RD, Wu CJ, Wang L. PMID: 30712845; PMCID: PMC6372356.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansAnimalsCells
    67. Inhibition of chemotherapy resistant breast cancer stem cells by a ROR1 specific antibody. Proc Natl Acad Sci U S A. 2019 01 22; 116(4):1370-1377. Zhang S, Zhang H, Ghia EM, Huang J, Wu L, Zhang J, Lam S, Lei Y, He J, Cui B, Widhopf GF, Yu J, Schwab R, Messer K, Jiang W, Parker BA, Carson DA, Kipps TJ. PMID: 30622177; PMCID: PMC6347692.
      View in: PubMed   Mentions: 46     Fields:    Translation:HumansAnimalsCells
    68. NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2019. J Natl Compr Canc Netw. 2019 Jan; 17(1):12-20. Wierda WG, Byrd JC, Abramson JS, Bilgrami SF, Bociek G, Brander D, Brown J, Chanan-Khan AA, Chavez JC, Coutre SE, Davis RS, Fletcher CD, Hill B, Kahl BS, Kamdar M, Kaplan LD, Khan N, Kipps TJ, Ma S, Malek S, Mato A, Mosse C, Neppalli VT, Shadman M, Siddiqi T, Stephens D, Wagner N, Dwyer MA, Sundar H. PMID: 30659125.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    69. Durable remissions with obinutuzumab-based chemoimmunotherapy: long-term follow-up of the phase 1b GALTON trial in CLL. Blood. 2019 02 28; 133(9):990-992. Brown JR, O'Brien S, Kingsley CD, Eradat H, Pagel JM, Hirata J, McIver T, Morariu-Zamfir R, Kipps TJ. PMID: 30593446.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    70. Wnt5a causes ROR1 to complex and activate cortactin to enhance migration of chronic lymphocytic leukemia cells. Leukemia. 2019 03; 33(3):653-661. Hasan MK, Rassenti L, Widhopf GF, Yu J, Kipps TJ. PMID: 30568170; PMCID: PMC6462876.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCells
    71. Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study. J Clin Oncol. 2019 02 01; 37(4):269-277. Kater AP, Seymour JF, Hillmen P, Eichhorst B, Langerak AW, Owen C, Verdugo M, Wu J, Punnoose EA, Jiang Y, Wang J, Boyer M, Humphrey K, Mobasher M, Kipps TJ. PMID: 30523712.
      View in: PubMed   Mentions: 84     Fields:    Translation:HumansCTClinical Trials
    72. SET alpha and SET beta mRNA isoforms in chronic lymphocytic leukaemia. Br J Haematol. 2019 02; 184(4):605-615. Brander DM, Friedman DR, Volkheimer AD, Christensen DJ, Rassenti LZ, Kipps TJ, Guadalupe E, Chen Y, Zhang D, Wang X, Davis C, Owzar K, Weinberg JB. PMID: 30443898; PMCID: PMC8375670.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCellsCTClinical Trials
    73. Single-agent ibrutinib versus chemoimmunotherapy regimens for treatment-naïve patients with chronic lymphocytic leukemia: A cross-trial comparison of phase 3 studies. Am J Hematol. 2018 11; 93(11):1402-1410. Robak T, Burger JA, Tedeschi A, Barr PM, Owen C, Bairey O, Hillmen P, Simpson D, Grosicki S, Devereux S, McCarthy H, Coutre SE, Quach H, Gaidano G, Maslyak Z, Stevens DA, Moreno C, Gill DS, Flinn IW, Gribben JG, Mokatrin A, Cheng M, Styles L, James DF, Kipps TJ, Ghia P. PMID: 30129285; PMCID: PMC6221114.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    74. Splicing modulation sensitizes chronic lymphocytic leukemia cells to venetoclax by remodeling mitochondrial apoptotic dependencies. JCI Insight. 2018 10 04; 3(19). Ten Hacken E, Valentin R, Regis FFD, Sun J, Yin S, Werner L, Deng J, Gruber M, Wong J, Zheng M, Gill AL, Seiler M, Smith P, Thomas M, Buonamici S, Ghia EM, Kim E, Rassenti LZ, Burger JA, Kipps TJ, Meyerson ML, Bachireddy P, Wang L, Reed R, Neuberg D, Carrasco RD, Brooks AN, Letai A, Davids MS, Wu CJ. PMID: 30282833; PMCID: PMC6237462.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansAnimalsCells
    75. Characterizing the kinetics of lymphocytosis in patients with chronic lymphocytic leukemia treated with single-agent ibrutinib. Leuk Lymphoma. 2019 04; 60(4):1000-1005. Barrientos JC, Burger JA, Byrd JC, Hillmen P, Zhou C, Ninomoto J, James DF, Kipps TJ. PMID: 30277101.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    76. miR-125a and miR-34a expression predicts Richter syndrome in chronic lymphocytic leukemia patients. Blood. 2018 11 15; 132(20):2179-2182. Balatti V, Tomasello L, Rassenti LZ, Veneziano D, Nigita G, Wang HY, Thorson JA, Kipps TJ, Pekarsky Y, Croce CM. PMID: 30242085; PMCID: PMC6238191.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCells
    77. Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2. Haematologica. 2018 09; 103(9):1502-1510. Barr PM, Robak T, Owen C, Tedeschi A, Bairey O, Bartlett NL, Burger JA, Hillmen P, Coutre S, Devereux S, Grosicki S, McCarthy H, Li J, Simpson D, Offner F, Moreno C, Zhou C, Styles L, James D, Kipps TJ, Ghia P. PMID: 29880603; PMCID: PMC6119145.
      View in: PubMed   Mentions: 42     Fields:    Translation:HumansCTClinical Trials
    78. Phase I Trial: Cirmtuzumab Inhibits ROR1 Signaling and Stemness Signatures in Patients with Chronic Lymphocytic Leukemia. Cell Stem Cell. 2018 Jun 01; 22(6):951-959.e3. Choi MY, Widhopf GF, Ghia EM, Kidwell RL, Hasan MK, Yu J, Rassenti LZ, Chen L, Chen Y, Pittman E, Pu M, Messer K, Prussak CE, Castro JE, Jamieson C, Kipps TJ. PMID: 29859176; PMCID: PMC7001723.
      View in: PubMed   Mentions: 54     Fields:    Translation:HumansCellsCTClinical Trials
    79. Cirmtuzumab inhibits ibrutinib-resistant, Wnt5a-induced Rac1 activation and proliferation in mantle cell lymphoma. Oncotarget. 2018 May 15; 9(37):24731-24736. Yu J, Chen Y, Chen L, Zhang L, Rassenti LZ, Widhopf GF, Kipps TJ. PMID: 29872501; PMCID: PMC5973864.
      View in: PubMed   Mentions: 9     Fields:    
    80. Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical Trials. JAMA Oncol. 2018 05 01; 4(5):712-716. O'Brien SM, Jaglowski S, Byrd JC, Bannerji R, Blum KA, Fox CP, Furman RR, Hillmen P, Kipps TJ, Montillo M, Sharman J, Suzuki S, James DF, Chu AD, Coutre SE. PMID: 29470582; PMCID: PMC5885180.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCTClinical Trials
    81. Wnt5a induces ROR1 to recruit DOCK2 to activate Rac1/2 in chronic lymphocytic leukemia. Blood. 2018 07 12; 132(2):170-178. Hasan MK, Yu J, Widhopf GF, Rassenti LZ, Chen L, Shen Z, Briggs SP, Neuberg DS, Kipps TJ. PMID: 29678828; PMCID: PMC6043980.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansAnimalsCells
    82. Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. N Engl J Med. 2018 Mar 22; 378(12):1107-1120. Seymour JF, Kipps TJ, Eichhorst B, Hillmen P, D'Rozario J, Assouline S, Owen C, Gerecitano J, Robak T, De la Serna J, Jaeger U, Cartron G, Montillo M, Humerickhouse R, Punnoose EA, Li Y, Boyer M, Humphrey K, Mobasher M, Kater AP. PMID: 29562156.
      View in: PubMed   Mentions: 228     Fields:    Translation:HumansCTClinical Trials
    83. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018 06 21; 131(25):2745-2760. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, Hillmen P, Keating M, Montserrat E, Chiorazzi N, Stilgenbauer S, Rai KR, Byrd JC, Eichhorst B, O'Brien S, Robak T, Seymour JF, Kipps TJ. PMID: 29540348.
      View in: PubMed   Mentions: 322     Fields:    Translation:Humans
    84. Commonly Occurring Cell Subsets in High-Grade Serous Ovarian Tumors Identified by Single-Cell Mass Cytometry. Cell Rep. 2018 02 13; 22(7):1875-1888. Gonzalez VD, Samusik N, Chen TJ, Savig ES, Aghaeepour N, Quigley DA, Huang YW, Giangarrà V, Borowsky AD, Hubbard NE, Chen SY, Han G, Ashworth A, Kipps TJ, Berek JS, Nolan GP, Fantl WJ. PMID: 29444438; PMCID: PMC8556706.
      View in: PubMed   Mentions: 39     Fields:    Translation:HumansCells
    85. Prognostic Testing Patterns and Outcomes of Chronic Lymphocytic Leukemia Patients Stratified by Fluorescence In Situ Hybridization/Cytogenetics: A Real-world Clinical Experience in the Connect CLL Registry. Clin Lymphoma Myeloma Leuk. 2018 02; 18(2):114-124.e2. Mato A, Nabhan C, Kay NE, Lamanna N, Kipps TJ, Grinblatt DL, Flowers CR, Farber CM, Davids MS, Kiselev P, Swern AS, Bhushan S, Sullivan K, Flick ED, Sharman JP. PMID: 29352719.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCellsCTClinical Trials
    86. Survival adjusting for crossover: phase 3 study of ibrutinib vs. chlorambucil in older patients with untreated chronic lymphocytic leukemia/small lymphocytic lymphoma. Haematologica. 2018 06; 103(6):e249-e251. Coutre S, Tedeschi A, Robak T, Barr PM, Owen C, Bairey O, Burger J, Zhou C, Styles L, James DF, Kipps TJ. PMID: 29170253; PMCID: PMC6058772.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    87. Hairy Cell Leukemia, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017 11; 15(11):1414-1427. Wierda WG, Byrd JC, Abramson JS, Bhat S, Bociek G, Brander D, Brown J, Chanan-Khan A, Coutre SE, Davis RS, Fletcher CD, Hill B, Kahl BS, Kamdar M, Kaplan LD, Khan N, Kipps TJ, Lancet J, Ma S, Malek S, Mosse C, Shadman M, Siddiqi T, Stephens D, Wagner N, Zelenetz AD, Dwyer MA, Sundar H. PMID: 29118233.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    88. Corrigendum to "Wnt5a Signaling in Normal and Cancer Stem Cells". Stem Cells Int. 2017; 2017:3467360. Zhou Y, Kipps TJ, Zhang S. PMID: 29098008; PMCID: PMC5643122.
      View in: PubMed   Mentions: 1  
    89. MicroRNA dysregulation to identify therapeutic target combinations for chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2017 10 03; 114(40):10731-10736. Rassenti LZ, Balatti V, Ghia EM, Palamarchuk A, Tomasello L, Fadda P, Pekarsky Y, Widhopf GF, Kipps TJ, Croce CM. PMID: 28923920; PMCID: PMC5635897.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCells
    90. Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials. Haematologica. 2017 10; 102(10):1796-1805. Brown JR, Moslehi J, O'Brien S, Ghia P, Hillmen P, Cymbalista F, Shanafelt TD, Fraser G, Rule S, Kipps TJ, Coutre S, Dilhuydy MS, Cramer P, Tedeschi A, Jaeger U, Dreyling M, Byrd JC, Howes A, Todd M, Vermeulen J, James DF, Clow F, Styles L, Valentino R, Wildgust M, Mahler M, Burger JA. PMID: 28751558; PMCID: PMC5622864.
      View in: PubMed   Mentions: 78     Fields:    Translation:Humans
    91. Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL. Leukemia. 2018 01; 32(1):83-91. Brown JR, Hillmen P, O'Brien S, Barrientos JC, Reddy NM, Coutre SE, Tam CS, Mulligan SP, Jaeger U, Barr PM, Furman RR, Kipps TJ, Cymbalista F, Thornton P, Caligaris-Cappio F, Delgado J, Montillo M, DeVos S, Moreno C, Pagel JM, Munir T, Burger JA, Chung D, Lin J, Gau L, Chang B, Cole G, Hsu E, James DF, Byrd JC. PMID: 28592889; PMCID: PMC5770586.
      View in: PubMed   Mentions: 81     Fields:    Translation:HumansCTClinical Trials
    92. Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemia. J Hematol Oncol. 2017 05 19; 10(1):112. Kashyap MK, Amaya-Chanaga CI, Kumar D, Simmons B, Huser N, Gu Y, Hallin M, Lindquist K, Yafawi R, Choi MY, Amine AA, Rassenti LZ, Zhang C, Liu SH, Smeal T, Fantin VR, Kipps TJ, Pernasetti F, Castro JE. PMID: 28526063; PMCID: PMC5438492.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansAnimalsCells
    93. Wnt5a induces ROR1 to associate with 14-3-3ζ for enhanced chemotaxis and proliferation of chronic lymphocytic leukemia cells. Leukemia. 2017 12; 31(12):2608-2614. Yu J, Chen L, Chen Y, Hasan MK, Ghia EM, Zhang L, Wu R, Rassenti LZ, Widhopf GF, Shen Z, Briggs SP, Kipps TJ. PMID: 28465528; PMCID: PMC5670032.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansAnimalsCells
    94. Wnt5a induces ROR1 to complex with HS1 to enhance migration of chronic lymphocytic leukemia cells. Leukemia. 2017 12; 31(12):2615-2622. Hasan MK, Yu J, Chen L, Cui B, Widhopf Ii GF, Rassenti L, Shen Z, Briggs SP, Kipps TJ. PMID: 28465529; PMCID: PMC5670028.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCells
    95. The long noncoding RNA, treRNA, decreases DNA damage and is associated with poor response to chemotherapy in chronic lymphocytic leukemia. Oncotarget. 2017 Apr 18; 8(16):25942-25954. Miller CR, Ruppert AS, Fobare S, Chen TL, Liu C, Lehman A, Blachly JS, Zhang X, Lucas DM, Grever MR, Tallman MS, Flinn IW, Rassenti LZ, Kipps TJ, Sampath D, Coombes KR, Hertlein EK. PMID: 28412730; PMCID: PMC5432228.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    96. Wnt5a Signaling in Normal and Cancer Stem Cells. Stem Cells Int. 2017; 2017:5295286. Zhou Y, Kipps TJ, Zhang S. PMID: 28491097; PMCID: PMC5405594.
      View in: PubMed   Mentions: 28  
    97. Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib. Br J Haematol. 2017 07; 178(2):286-291. Jones JA, Hillmen P, Coutre S, Tam C, Furman RR, Barr PM, Schuster SJ, Kipps TJ, Flinn IW, Jaeger U, Burger JA, Cheng M, Ninomoto J, James DF, Byrd JC, O'Brien SM. PMID: 28397242; PMCID: PMC6084297.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCTClinical Trials
    98. Venetoclax and obinutuzumab in chronic lymphocytic leukemia. Blood. 2017 05 11; 129(19):2702-2705. Fischer K, Al-Sawaf O, Fink AM, Dixon M, Bahlo J, Warburton S, Kipps TJ, Weinkove R, Robinson S, Seiler T, Opat S, Owen C, López J, Humphrey K, Humerickhouse R, Tausch E, Frenzel L, Eichhorst B, Wendtner CM, Stilgenbauer S, Langerak AW, van Dongen JJM, Böttcher S, Ritgen M, Goede V, Mobasher M, Hallek M. PMID: 28325865; PMCID: PMC5437733.
      View in: PubMed   Mentions: 44     Fields:    Translation:HumansCTClinical Trials
    99. Chronic lymphocytic leukaemia. Nat Rev Dis Primers. 2017 02 09; 3:17008. Kipps TJ, Stevenson FK, Wu CJ, Croce CM, Packham G, Wierda WG, O'Brien S, Gribben J, Rai K. PMID: 28179635.
      View in: PubMed   Mentions: 35     Fields:    Translation:Humans
    100. Leukemia-cell proliferation and disease progression in patients with early stage chronic lymphocytic leukemia. Leukemia. 2017 06; 31(6):1348-1354. Murphy EJ, Neuberg DS, Rassenti LZ, Hayes G, Redd R, Emson C, Li K, Brown JR, Wierda WG, Turner S, Greaves AW, Zent CS, Byrd JC, McConnel C, Barrientos J, Kay N, Hellerstein MK, Chiorazzi N, Kipps TJ, Rai KR. PMID: 28115735; PMCID: PMC5462857.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    101. Chronic lymphocytic leukaemia. Nat Rev Dis Primers. 2017 01 19; 3:16096. Kipps TJ, Stevenson FK, Wu CJ, Croce CM, Packham G, Wierda WG, O'Brien S, Gribben J, Rai K. PMID: 28102226; PMCID: PMC5336551.
      View in: PubMed   Mentions: 149     Fields:    Translation:Humans
    102. Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma. J Clin Oncol. 2017 Mar 10; 35(8):826-833. Davids MS, Roberts AW, Seymour JF, Pagel JM, Kahl BS, Wierda WG, Puvvada S, Kipps TJ, Anderson MA, Salem AH, Dunbar M, Zhu M, Peale F, Ross JA, Gressick L, Desai M, Kim SY, Verdugo M, Humerickhouse RA, Gordon GB, Gerecitano JF. PMID: 28095146; PMCID: PMC5455685.
      View in: PubMed   Mentions: 223     Fields:    Translation:Humans
    103. Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study. Lancet Oncol. 2017 Feb; 18(2):230-240. Seymour JF, Ma S, Brander DM, Choi MY, Barrientos J, Davids MS, Anderson MA, Beaven AW, Rosen ST, Tam CS, Prine B, Agarwal SK, Munasinghe W, Zhu M, Lash LL, Desai M, Cerri E, Verdugo M, Kim SY, Humerickhouse RA, Gordon GB, Kipps TJ, Roberts AW. PMID: 28089635; PMCID: PMC5316338.
      View in: PubMed   Mentions: 99     Fields:    Translation:HumansCTClinical Trials
    104. hBfl-1/hNOXA Interaction Studies Provide New Insights on the Role of Bfl-1 in Cancer Cell Resistance and for the Design of Novel Anticancer Agents. ACS Chem Biol. 2017 02 17; 12(2):444-455. Barile E, Marconi GD, De SK, Baggio C, Gambini L, Salem AF, Kashyap MK, Castro JE, Kipps TJ, Pellecchia M. PMID: 28026162; PMCID: PMC5320539.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCells
    105. Cirmtuzumab inhibits Wnt5a-induced Rac1 activation in chronic lymphocytic leukemia treated with ibrutinib. Leukemia. 2017 06; 31(6):1333-1339. Yu J, Chen L, Cui B, Wu C, Choi MY, Chen Y, Zhang L, Rassenti LZ, Widhopf Ii GF, Kipps TJ. PMID: 27904138; PMCID: PMC5462858.
      View in: PubMed   Mentions: 39     Fields:    Translation:HumansAnimalsCells
    106. EGR2 mutations define a new clinically aggressive subgroup of chronic lymphocytic leukemia. Leukemia. 2017 07; 31(7):1547-1554. Young E, Noerenberg D, Mansouri L, Ljungström V, Frick M, Sutton LA, Blakemore SJ, Galan-Sousa J, Plevova K, Baliakas P, Rossi D, Clifford R, Roos-Weil D, Navrkalova V, Dörken B, Schmitt CA, Smedby KE, Juliusson G, Giacopelli B, Blachly JS, Belessi C, Panagiotidis P, Chiorazzi N, Davi F, Langerak AW, Oscier D, Schuh A, Gaidano G, Ghia P, Xu W, Fan L, Bernard OA, Nguyen-Khac F, Rassenti L, Li J, Kipps TJ, Stamatopoulos K, Pospisilova S, Zenz T, Oakes CC, Strefford JC, Rosenquist R, Damm F. PMID: 27890934; PMCID: PMC7001738.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    107. Real-world clinical experience in the Connect® chronic lymphocytic leukaemia registry: a prospective cohort study of 1494 patients across 199 US centres. Br J Haematol. 2016 Dec; 175(5):892-903. Mato A, Nabhan C, Kay NE, Weiss MA, Lamanna N, Kipps TJ, Grinblatt DL, Flinn IW, Kozloff MF, Flowers CR, Farber CM, Kiselev P, Swern AS, Sullivan K, Flick ED, Sharman JP. PMID: 27861736; PMCID: PMC5132115.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    108. High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia. Blood. 2016 12 22; 128(25):2931-2940. Cui B, Ghia EM, Chen L, Rassenti LZ, DeBoever C, Widhopf GF, Yu J, Neuberg DS, Wierda WG, Rai KR, Kay NE, Brown JR, Jones JA, Gribben JG, Frazer KA, Kipps TJ. PMID: 27815263; PMCID: PMC5179332.
      View in: PubMed   Mentions: 50     Fields:    Translation:HumansCells
    109. Transcriptomic Characterization of SF3B1 Mutation Reveals Its Pleiotropic Effects in Chronic Lymphocytic Leukemia. Cancer Cell. 2016 Nov 14; 30(5):750-763. Wang L, Brooks AN, Fan J, Wan Y, Gambe R, Li S, Hergert S, Yin S, Freeman SS, Levin JZ, Fan L, Seiler M, Buonamici S, Smith PG, Chau KF, Cibulskis CL, Zhang W, Rassenti LZ, Ghia EM, Kipps TJ, Fernandes S, Bloch DB, Kotliar D, Landau DA, Shukla SA, Aster JC, Reed R, DeLuca DS, Brown JR, Neuberg D, Getz G, Livak KJ, Meyerson MM, Kharchenko PV, Wu CJ. PMID: 27818134; PMCID: PMC5127278.
      View in: PubMed   Mentions: 83     Fields:    Translation:HumansCells
    110. Dynamic changes in CCL3 and CCL4 plasma concentrations in patients with chronic lymphocytic leukaemia managed with observation. Br J Haematol. 2018 02; 180(4):597-600. Sivina M, Werner L, Rassenti L, Ferrajoli A, Wierda WG, Keating MJ, O'Brien S, Neuberg D, Kipps T, Burger JA. PMID: 27766619; PMCID: PMC7021206.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    111. How Do Targeted Therapies Change the Management of Indolent Lymphomas? Oncology (Williston Park). 2016 09 15; 30(9):859-60. Choi MY, Kipps TJ. PMID: 27633418.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    112. Upregulation of long noncoding RNA MIAT in aggressive form of chronic lymphocytic leukemias. Oncotarget. 2016 08 23; 7(34):54174-54182. Sattari A, Siddiqui H, Moshiri F, Ngankeu A, Nakamura T, Kipps TJ, Croce CM. PMID: 27527866; PMCID: PMC5338916.
      View in: PubMed   Mentions: 34     Fields:    Translation:HumansCells
    113. Adoptive cellular therapy for chronic lymphocytic leukemia and B cell malignancies. CARs and more. Best Pract Res Clin Haematol. 2016 03; 29(1):15-29. Castro JE, Kipps TJ. PMID: 27742068.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    114. Selectivity in Small Molecule Splicing Modulation. ACS Chem Biol. 2016 10 21; 11(10):2716-2723. Kumar D, Kashyap MK, La Clair JJ, Villa R, Spaanderman I, Chien S, Rassenti LZ, Kipps TJ, Burkart MD, Castro JE. PMID: 27499047.
      View in: PubMed   Mentions: 10     Fields:    Translation:Cells
    115. Ibrutinib inhibits CD20 upregulation on CLL B cells mediated by the CXCR4/SDF-1 axis. Blood. 2016 09 22; 128(12):1609-13. Pavlasova G, Borsky M, Seda V, Cerna K, Osickova J, Doubek M, Mayer J, Calogero R, Trbusek M, Pospisilova S, Davids MS, Kipps TJ, Brown JR, Mraz M. PMID: 27480113; PMCID: PMC5291297.
      View in: PubMed   Mentions: 34     Fields:    Translation:HumansCells
    116. ATM Mutations in Cancer: Therapeutic Implications. Mol Cancer Ther. 2016 08; 15(8):1781-91. Choi M, Kipps T, Kurzrock R. PMID: 27413114.
      View in: PubMed   Mentions: 165     Fields:    Translation:HumansAnimals
    117. Associations of ofatumumab exposure and treatment outcomes in patients with untreated CLL receiving chemoimmunotherapy. Leuk Lymphoma. 2017 02; 58(2):348-356. Jewell RC, Kipps TJ, Dürig J, Griskevicius L, Stilgenbauer S, Smolej L, Mayer J, Hess G, Hernandez-Ilizaliturri FJ, Padmanabhan-Iyer S, Fang L, Goldstein N, Gorczyca M, Gupta I, Lisby S, Wierda WG, Hx-CD20-407 Study Investigators. PMID: 27389174; PMCID: PMC7053426.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    118. Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity. Blood. 2016 07 14; 128(2):195-203. Lampson BL, Kasar SN, Matos TR, Morgan EA, Rassenti L, Davids MS, Fisher DC, Freedman AS, Jacobson CA, Armand P, Abramson JS, Arnason JE, Kipps TJ, Fein J, Fernandes S, Hanna J, Ritz J, Kim HT, Brown JR. PMID: 27247136; PMCID: PMC4946200.
      View in: PubMed   Mentions: 120     Fields:    Translation:HumansCTClinical Trials
    119. Phase I study of single-agent CC-292, a highly selective Bruton's tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia. Haematologica. 2016 07; 101(7):e295-8. Brown JR, Harb WA, Hill BT, Gabrilove J, Sharman JP, Schreeder MT, Barr PM, Foran JM, Miller TP, Burger JA, Kelly KR, Mahadevan D, Ma S, Li Y, Pierce DW, Barnett E, Marine J, Miranda M, Azaryan A, Yu X, Nava-Parada P, Mei J, Kipps TJ. PMID: 27151992; PMCID: PMC5004476.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansCTClinical Trials
    120. Dielectrophoretic recovery of DNA from plasma for the identification of chronic lymphocytic leukemia point mutations. Int J Hematol Oncol. 2016 May; 5(1):27-35. Manouchehri S, Ibsen S, Wright J, Rassenti L, Ghia EM, Widhopf GF, Kipps TJ, Heller MJ. PMID: 30302201; PMCID: PMC6171991.
      View in: PubMed   Mentions: 8  
    121. The Cell Surface Receptor CD44: NMR-Based Characterization of Putative Ligands. ChemMedChem. 2016 05 19; 11(10):1097-106. Baggio C, Barile E, Di Sorbo G, Kipps TJ, Pellecchia M. PMID: 27144715; PMCID: PMC5271563.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    122. Ibrutinib for Chronic Lymphocytic Leukemia. N Engl J Med. 2016 04 21; 374(16):1594-5. Burger JA, Styles L, Kipps TJ. PMID: 27096594.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    123. Dysregulation of a family of short noncoding RNAs, tsRNAs, in human cancer. Proc Natl Acad Sci U S A. 2016 May 03; 113(18):5071-6. Pekarsky Y, Balatti V, Palamarchuk A, Rizzotto L, Veneziano D, Nigita G, Rassenti LZ, Pass HI, Kipps TJ, Liu CG, Croce CM. PMID: 27071132; PMCID: PMC4983805.
      View in: PubMed   Mentions: 101     Fields:    Translation:Humans
    124. Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial. Blood Cancer J. 2016 Mar 11; 6:e404. Bühler A, Wendtner CM, Kipps TJ, Rassenti L, Fraser GA, Michallet AS, Hillmen P, Dürig J, Gregory SA, Kalaycio M, Aurran-Schleinitz T, Trentin L, Gribben JG, Chanan-Khan A, Purse B, Zhang J, De Bedout S, Mei J, Hallek M, Stilgenbauer S. PMID: 26967821; PMCID: PMC4817104.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    125. The Dohner fluorescence in situ hybridization prognostic classification of chronic lymphocytic leukaemia (CLL): the CLL Research Consortium experience. Br J Haematol. 2016 Apr; 173(1):105-13. Van Dyke DL, Werner L, Rassenti LZ, Neuberg D, Ghia E, Heerema NA, Dal Cin P, Dell Aquila M, Sreekantaiah C, Greaves AW, Kipps TJ, Kay NE. PMID: 26848054; PMCID: PMC4963001.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCellsCTClinical Trials
    126. Wnt5a induces ROR1/ROR2 heterooligomerization to enhance leukemia chemotaxis and proliferation. J Clin Invest. 2016 Feb; 126(2):585-98. Yu J, Chen L, Cui B, Widhopf GF, Shen Z, Wu R, Zhang L, Zhang S, Briggs SP, Kipps TJ. PMID: 26690702; PMCID: PMC4731190.
      View in: PubMed   Mentions: 85     Fields:    Translation:HumansAnimalsCells
    127. Ulocuplumab (BMS-936564 / MDX1338): a fully human anti-CXCR4 antibody induces cell death in chronic lymphocytic leukemia mediated through a reactive oxygen species-dependent pathway. Oncotarget. 2016 Jan 19; 7(3):2809-22. Kashyap MK, Kumar D, Jones H, Amaya-Chanaga CI, Choi MY, Melo-Cardenas J, Ale-Ali A, Kuhne MR, Sabbatini P, Cohen LJ, Shelat SG, Rassenti LZ, Kipps TJ, Cardarelli PM, Castro JE. PMID: 26646452; PMCID: PMC4823073.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansCells
    128. DNA methylation dynamics during B cell maturation underlie a continuum of disease phenotypes in chronic lymphocytic leukemia. Nat Genet. 2016 Mar; 48(3):253-64. Oakes CC, Seifert M, Assenov Y, Gu L, Przekopowitz M, Ruppert AS, Wang Q, Imbusch CD, Serva A, Koser SD, Brocks D, Lipka DB, Bogatyrova O, Weichenhan D, Brors B, Rassenti L, Kipps TJ, Mertens D, Zapatka M, Lichter P, Döhner H, Küppers R, Zenz T, Stilgenbauer S, Byrd JC, Plass C. PMID: 26780610; PMCID: PMC4963005.
      View in: PubMed   Mentions: 123     Fields:    Translation:HumansCells
    129. Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial. Leuk Lymphoma. 2016; 57(6):1291-9. Wendtner CM, Hallek M, Fraser GA, Michallet AS, Hillmen P, Dürig J, Kalaycio M, Gribben JG, Stilgenbauer S, Buhler A, Kipps TJ, Purse B, Zhang J, De Bedout S, Mei J, Chanan-Khan A. PMID: 26763349; PMCID: PMC7063681.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    130. A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study. Leukemia. 2016 Apr; 30(4):929-36. Rawstron AC, Fazi C, Agathangelidis A, Villamor N, Letestu R, Nomdedeu J, Palacio C, Stehlikova O, Kreuzer KA, Liptrot S, O'Brien D, de Tute RM, Marinov I, Hauwel M, Spacek M, Dobber J, Kater AP, Gambell P, Soosapilla A, Lozanski G, Brachtl G, Lin K, Boysen J, Hanson C, Jorgensen JL, Stetler-Stevenson M, Yuan C, Broome HE, Rassenti L, Craig F, Delgado J, Moreno C, Bosch F, Egle A, Doubek M, Pospisilova S, Mulligan S, Westerman D, Sanders CM, Emerson R, Robins HS, Kirsch I, Shanafelt T, Pettitt A, Kipps TJ, Wierda WG, Cymbalista F, Hallek M, Hillmen P, Montserrat E, Ghia P. PMID: 26639181; PMCID: PMC4832072.
      View in: PubMed   Mentions: 59     Fields:    Translation:Humans
    131. Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. N Engl J Med. 2015 Dec 17; 373(25):2425-37. Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P, Bairey O, Hillmen P, Bartlett NL, Li J, Simpson D, Grosicki S, Devereux S, McCarthy H, Coutre S, Quach H, Gaidano G, Maslyak Z, Stevens DA, Janssens A, Offner F, Mayer J, O'Dwyer M, Hellmann A, Schuh A, Siddiqi T, Polliack A, Tam CS, Suri D, Cheng M, Clow F, Styles L, James DF, Kipps TJ, RESONATE-2 Investigators. PMID: 26639149; PMCID: PMC4722809.
      View in: PubMed   Mentions: 460     Fields:    Translation:HumansCTClinical Trials
    132. Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. N Engl J Med. 2016 Jan 28; 374(4):311-22. Roberts AW, Davids MS, Pagel JM, Kahl BS, Puvvada SD, Gerecitano JF, Kipps TJ, Anderson MA, Brown JR, Gressick L, Wong S, Dunbar M, Zhu M, Desai MB, Cerri E, Heitner Enschede S, Humerickhouse RA, Wierda WG, Seymour JF. PMID: 26639348; PMCID: PMC7107002.
      View in: PubMed   Mentions: 651     Fields:    Translation:HumansCTClinical Trials
    133. A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia. Blood. 2015 Dec 17; 126(25):2686-94. O'Brien SM, Lamanna N, Kipps TJ, Flinn I, Zelenetz AD, Burger JA, Keating M, Mitra S, Holes L, Yu AS, Johnson DM, Miller LL, Kim Y, Dansey RD, Dubowy RL, Coutre SE. PMID: 26472751; PMCID: PMC4732760.
      View in: PubMed   Mentions: 95     Fields:    Translation:HumansCTClinical Trials
    134. Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia. Blood. 2016 Jan 07; 127(1):79-86. Byrd JC, Flynn JM, Kipps TJ, Boxer M, Kolibaba KS, Carlile DJ, Fingerle-Rowson G, Tyson N, Hirata J, Sharman JP. PMID: 26472752; PMCID: PMC4705612.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCTClinical Trials
    135. Quaking and miR-155 interactions in inflammation and leukemogenesis. Oncotarget. 2015 Sep 22; 6(28):24599-610. Tili E, Chiabai M, Palmieri D, Brown M, Cui R, Fernandes C, Richmond T, Kim T, Sheetz T, Sun HL, Lagana A, Veneziano D, Volinia S, Rassenti L, Kipps T, Awad H, Michaille JJ, Croce CM. PMID: 26337206; PMCID: PMC4694781.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansAnimalsCells
    136. An open-label, single-arm, phase 1 study to assess biomarker effects, efficacy and safety of ofatumumab in patients with refractory chronic lymphocytic leukemia. Leuk Lymphoma. 2015; 56(10):2819-25. Patton WN, Lindeman R, Butler AC, Kipps TJ, Jewell RC, Laubscher KH, Zhou YY, Lewis E, Sedoti D, Witman P, Fang L, Chan G. PMID: 25721750; PMCID: PMC4654681.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCellsCTClinical Trials
    137. In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc. 2015 Aug; 90(8):996-1000. Tefferi A, Kantarjian H, Rajkumar SV, Baker LH, Abkowitz JL, Adamson JW, Advani RH, Allison J, Antman KH, Bast RC, Bennett JM, Benz EJ, Berliner N, Bertino J, Bhatia R, Bhatia S, Bhojwani D, Blanke CD, Bloomfield CD, Bosserman L, Broxmeyer HE, Byrd JC, Cabanillas F, Canellos GP, Chabner BA, Chanan-Khan A, Cheson B, Clarkson B, Cohn SL, Colon-Otero G, Cortes J, Coutre S, Cristofanilli M, Curran WJ, Daley GQ, DeAngelo DJ, Deeg HJ, Einhorn LH, Erba HP, Esteva FJ, Estey E, Fidler IJ, Foran J, Forman S, Freireich E, Fuchs C, George JN, Gertz MA, Giralt S, Golomb H, Greenberg P, Gutterman J, Handin RI, Hellman S, Hoff PM, Hoffman R, Hong WK, Horowitz M, Hortobagyi GN, Hudis C, Issa JP, Johnson BE, Kantoff PW, Kaushansky K, Khayat D, Khuri FR, Kipps TJ, Kripke M, Kyle RA, Larson RA, Lawrence TS, Levine R, Link MP, Lippman SM, Lonial S, Lyman GH, Markman M, Mendelsohn J, Meropol NJ, Messinger Y, Mulvey TM, O'Brien S, Perez-Soler R, Pollock R, Prchal J, Press O, Radich J, Rai K, Rosenberg SA, Rowe JM, Rugo H, Runowicz CD, Sandmaier BM, Saven A, Schafer AI, Schiffer C, Sekeres MA, Silver RT, Siu LL, Steensma DP, Stewart FM, Stock W, Stone R, Storb R, Strong LC, Tallman MS, Thompson M, Ueno NT, Van Etten RA, Vose JM, Wiernik PH, Winer EP, Younes A, Zelenetz AD, LeMaistre CA. PMID: 26211600; PMCID: PMC5365030.
      View in: PubMed   Mentions: 44     Fields:    Translation:Humans
    138. Pre-clinical Specificity and Safety of UC-961, a First-In-Class Monoclonal Antibody Targeting ROR1. Clin Lymphoma Myeloma Leuk. 2015 Jun; 15 Suppl:S167-9. Choi MY, Widhopf GF, Wu CC, Cui B, Lao F, Sadarangani A, Cavagnaro J, Prussak C, Carson DA, Jamieson C, Kipps TJ. PMID: 26297272; PMCID: PMC4548279.
      View in: PubMed   Mentions: 53     Fields:    Translation:HumansCells
    139. Sleeping Beauty Transposition of Chimeric Antigen Receptors Targeting Receptor Tyrosine Kinase-Like Orphan Receptor-1 (ROR1) into Diverse Memory T-Cell Populations. PLoS One. 2015; 10(6):e0128151. Deniger DC, Yu J, Huls MH, Figliola MJ, Mi T, Maiti SN, Widhopf GF, Hurton LV, Thokala R, Singh H, Olivares S, Champlin RE, Wierda WG, Kipps TJ, Cooper LJ. PMID: 26030772; PMCID: PMC4451012.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansAnimalsCells
    140. A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia. Leuk Lymphoma. 2015; 56(10):2826-33. Kipps TJ, Eradat H, Grosicki S, Catalano J, Cosolo W, Dyagil IS, Yalamanchili S, Chai A, Sahasranaman S, Punnoose E, Hurst D, Pylypenko H. PMID: 25797560; PMCID: PMC4643417.
      View in: PubMed   Mentions: 79     Fields:    Translation:HumansCTClinical Trials
    141. AGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody-Drug Conjugate as a Potential Therapeutic for B/T-Cell Malignancies and AML: A New Role for CD37 in AML. Mol Cancer Ther. 2015 Jul; 14(7):1650-60. Pereira DS, Guevara CI, Jin L, Mbong N, Verlinsky A, Hsu SJ, Aviña H, Karki S, Abad JD, Yang P, Moon SJ, Malik F, Choi MY, An Z, Morrison K, Challita-Eid PM, Doñate F, Joseph IB, Kipps TJ, Dick JE, Stover DR. PMID: 25934707; PMCID: PMC4557793.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansAnimalsCells
    142. Epstein-Barr Virus MicroRNAs are Expressed in Patients with Chronic Lymphocytic Leukemia and Correlate with Overall Survival. EBioMedicine. 2015 Jun; 2(6):572-82. Ferrajoli A, Ivan C, Ciccone M, Shimizu M, Kita Y, Ohtsuka M, D'Abundo L, Qiang J, Lerner S, Nouraee N, Rabe KG, Rassenti LZ, Van Roosbroeck K, Manning JT, Yuan Y, Zhang X, Shanafelt TD, Wierda WG, Sabbioni S, Tarrand JJ, Estrov Z, Radovich M, Liang H, Negrini M, Kipps TJ, Kay NE, Keating M, Calin GA. PMID: 26288818; PMCID: PMC4535165.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansCells
    143. Genetic and epigenetic profiling of CLL disease progression reveals limited somatic evolution and suggests a relationship to memory-cell development. Blood Cancer J. 2015 Apr 10; 5:e303. Smith EN, Ghia EM, DeBoever CM, Rassenti LZ, Jepsen K, Yoon KA, Matsui H, Rozenzhak S, Alakus H, Shepard PJ, Dai Y, Khosroheidari M, Bina M, Gunderson KL, Messer K, Muthuswamy L, Hudson TJ, Harismendy O, Barrett CL, Jamieson CH, Carson DA, Kipps TJ, Frazer KA. PMID: 25860294; PMCID: PMC4450323.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCells
    144. Targeting the spliceosome in chronic lymphocytic leukemia with the macrolides FD-895 and pladienolide-B. Haematologica. 2015 Jul; 100(7):945-54. Kashyap MK, Kumar D, Villa R, La Clair JJ, Benner C, Sasik R, Jones H, Ghia EM, Rassenti LZ, Kipps TJ, Burkart MD, Castro JE. PMID: 25862704; PMCID: PMC4486229.
      View in: PubMed   Mentions: 39     Fields:    Translation:HumansAnimalsCells
    145. Immunoglobulin transcript sequence and somatic hypermutation computation from unselected RNA-seq reads in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2015 Apr 07; 112(14):4322-7. Blachly JS, Ruppert AS, Zhao W, Long S, Flynn J, Flinn I, Jones J, Maddocks K, Andritsos L, Ghia EM, Rassenti LZ, Kipps TJ, de la Chapelle A, Byrd JC. PMID: 25787252; PMCID: PMC4394264.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCells
    146. Transcriptome sequencing reveals potential mechanism of cryptic 3' splice site selection in SF3B1-mutated cancers. PLoS Comput Biol. 2015 Mar; 11(3):e1004105. DeBoever C, Ghia EM, Shepard PJ, Rassenti L, Barrett CL, Jepsen K, Jamieson CH, Carson D, Kipps TJ, Frazer KA. PMID: 25768983; PMCID: PMC4358997.
      View in: PubMed   Mentions: 116     Fields:    Translation:HumansCells
    147. Ofatumumab monotherapy in fludarabine-refractory chronic lymphocytic leukemia: final results from a pivotal study. Haematologica. 2015 Aug; 100(8):e311-4. Österborg A, Jewell RC, Padmanabhan-Iyer S, Kipps TJ, Mayer J, Stilgenbauer S, Williams CD, Hellmann A, Furman RR, Robak T, Hillmen P, Trnêný M, Dyer MJ, Piotrowska M, Kozak T, Gupta IV, Phillips JL, Goldstein N, Struemper H, Losic N, Lisby S, Wierda WG, Hx-CD20-406 Study Investigators. PMID: 25769539; PMCID: PMC5004432.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    148. Obinutuzumab plus fludarabine/cyclophosphamide or bendamustine in the initial therapy of CLL patients: the phase 1b GALTON trial. Blood. 2015 Apr 30; 125(18):2779-85. Brown JR, O'Brien S, Kingsley CD, Eradat H, Pagel JM, Lymp J, Hirata J, Kipps TJ. PMID: 25769620; PMCID: PMC4416529.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansCTClinical Trials
    149. Final results of EFC6663: a multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemia. Leuk Res. 2015 May; 39(5):495-500. Lanasa MC, Andritsos L, Brown JR, Gabrilove J, Caligaris-Cappio F, Ghia P, Larson RA, Kipps TJ, Leblond V, Milligan DW, Janssens A, Johnson AJ, Heerema NA, Bühler A, Stilgenbauer S, Devin J, Hallek M, Byrd JC, Grever MR. PMID: 25804339; PMCID: PMC4557608.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCTClinical Trials
    150. TCL1 targeting miR-3676 is codeleted with tumor protein p53 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2015 Feb 17; 112(7):2169-74. Balatti V, Rizzotto L, Miller C, Palamarchuk A, Fadda P, Pandolfo R, Rassenti LZ, Hertlein E, Ruppert AS, Lozanski A, Lozanski G, Kipps TJ, Byrd JC, Croce CM, Pekarsky Y. PMID: 25646413; PMCID: PMC4343115.
      View in: PubMed   Mentions: 37     Fields:    Translation:Humans
    151. Somatic MED12 mutations are associated with poor prognosis markers in chronic lymphocytic leukemia. Oncotarget. 2015 Jan 30; 6(3):1884-8. Kämpjärvi K, Järvinen TM, Heikkinen T, Ruppert AS, Senter L, Hoag KW, Dufva O, Kontro M, Rassenti L, Hertlein E, Kipps TJ, Porkka K, Byrd JC, de la Chapelle A, Vahteristo P. PMID: 25595892; PMCID: PMC4359339.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansCells
    152. Intratumoral injection of Ad-ISF35 (Chimeric CD154) breaks tolerance and induces lymphoma tumor regression. Hum Gene Ther. 2015 Jan; 26(1):14-25. Urquiza M, Melo-Cardenas J, Aguillon R, Kipps TJ, Castro JE. PMID: 25382101; PMCID: PMC4303189.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimalsCells
    153. A phase II study of the combination of rituximab and granulocyte macrophage colony stimulating factor as treatment of patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2015 Jun; 56(6):1878-80. Strati P, Tong WG, Vitale C, Wierda WG, O'Brien S, Brown JR, Weng WK, Kipps T, Keating MJ, Ferrajoli A. PMID: 25311497; PMCID: PMC4547465.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    154. Ovarian cancer stem cells express ROR1, which can be targeted for anti-cancer-stem-cell therapy. Proc Natl Acad Sci U S A. 2014 Dec 02; 111(48):17266-71. Zhang S, Cui B, Lai H, Liu G, Ghia EM, Widhopf GF, Zhang Z, Wu CC, Chen L, Wu R, Schwab R, Carson DA, Kipps TJ. PMID: 25411317; PMCID: PMC4260559.
      View in: PubMed   Mentions: 84     Fields:    Translation:HumansAnimalsCells
    155. Ofatumumab and high-dose methylprednisolone for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia. Blood Cancer J. 2014 Nov 14; 4:e258. Castro JE, Choi MY, Carvajal T, Almahasnah E, Chang J, James DF, Kipps TJ. PMID: 25397619; PMCID: PMC4571984.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCellsCTClinical Trials
    156. Biased estimates of clonal evolution and subclonal heterogeneity can arise from PCR duplicates in deep sequencing experiments. Genome Biol. 2014 Aug 07; 15(8):420. Smith EN, Jepsen K, Khosroheidari M, Rassenti LZ, D'Antonio M, Ghia EM, Carson DA, Jamieson CH, Kipps TJ, Frazer KA. PMID: 25103687; PMCID: PMC4165357.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    157. Lenalidomide inhibits the proliferation of CLL cells via a cereblon/p21(WAF1/Cip1)-dependent mechanism independent of functional p53. Blood. 2014 Sep 04; 124(10):1637-44. Fecteau JF, Corral LG, Ghia EM, Gaidarova S, Futalan D, Bharati IS, Cathers B, Schwaederlé M, Cui B, Lopez-Girona A, Messmer D, Kipps TJ. PMID: 24990888; PMCID: PMC4155272.
      View in: PubMed   Mentions: 36     Fields:    Translation:HumansCells
    158. MicroRNA-155 influences B-cell receptor signaling and associates with aggressive disease in chronic lymphocytic leukemia. Blood. 2014 Jul 24; 124(4):546-54. Cui B, Chen L, Zhang S, Mraz M, Fecteau JF, Yu J, Ghia EM, Zhang L, Bao L, Rassenti LZ, Messer K, Calin GA, Croce CM, Kipps TJ. PMID: 24914134; PMCID: PMC4110661.
      View in: PubMed   Mentions: 85     Fields:    Translation:HumansCells
    159. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014 Jul 17; 371(3):213-23. Byrd JC, Brown JR, O'Brien S, Barrientos JC, Kay NE, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Devereux S, Barr PM, Furman RR, Kipps TJ, Cymbalista F, Pocock C, Thornton P, Caligaris-Cappio F, Robak T, Delgado J, Schuster SJ, Montillo M, Schuh A, de Vos S, Gill D, Bloor A, Dearden C, Moreno C, Jones JJ, Chu AD, Fardis M, McGreivy J, Clow F, James DF, Hillmen P, RESONATE Investigators. PMID: 24881631; PMCID: PMC4134521.
      View in: PubMed   Mentions: 535     Fields:    Translation:Humans
    160. Lenalidomide and rituximab for the initial treatment of patients with chronic lymphocytic leukemia: a multicenter clinical-translational study from the chronic lymphocytic leukemia research consortium. J Clin Oncol. 2014 Jul 01; 32(19):2067-73. James DF, Werner L, Brown JR, Wierda WG, Barrientos JC, Castro JE, Greaves A, Johnson AJ, Rassenti LZ, Rai KR, Neuberg D, Kipps TJ. PMID: 24868031; PMCID: PMC4067945.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    161. Validation of ZAP-70 methylation and its relative significance in predicting outcome in chronic lymphocytic leukemia. Blood. 2014 Jul 03; 124(1):42-8. Claus R, Lucas DM, Ruppert AS, Williams KE, Weng D, Patterson K, Zucknick M, Oakes CC, Rassenti LZ, Greaves AW, Geyer S, Wierda WG, Brown JR, Gribben JG, Barrientos JC, Rai KR, Kay NE, Kipps TJ, Shields P, Zhao W, Grever MR, Plass C, Byrd JC. PMID: 24868078; PMCID: PMC4125353.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansCells
    162. Quantitative proteomics to characterize specific histone H2A proteolysis in chronic lymphocytic leukemia and the myeloid THP-1 cell line. Int J Mol Sci. 2014 May 27; 15(6):9407-21. Glibert P, Vossaert L, Van Steendam K, Lambrecht S, Van Nieuwerburgh F, Offner F, Kipps T, Dhaenens M, Deforce D. PMID: 24871368; PMCID: PMC4100102.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    163. Translocation t(2;11) in CLL cells results in CXCR4/MAML2 fusion oncogene. Blood. 2014 Jul 10; 124(2):259-62. Acunzo M, Romano G, Wernicke D, Balatti V, Rassenti LZ, dell'Aquila M, Kipps TJ, Pekarsky Y, Croce CM. PMID: 24855209; PMCID: PMC4093682.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansAnimalsCells
    164. Trisomy 12 chronic lymphocytic leukemia cells exhibit upregulation of integrin signaling that is modulated by NOTCH1 mutations. Blood. 2014 Jun 26; 123(26):4101-10. Riches JC, O'Donovan CJ, Kingdon SJ, McClanahan F, Clear AJ, Neuberg DS, Werner L, Croce CM, Ramsay AG, Rassenti LZ, Kipps TJ, Gribben JG. PMID: 24829201; PMCID: PMC4073326.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansCellsCTClinical Trials
    165. Dielectrophoretic isolation and detection of cancer-related circulating cell-free DNA biomarkers from blood and plasma. Electrophoresis. 2014 Jul; 35(12-13):1828-36. Sonnenberg A, Marciniak JY, Skowronski EA, Manouchehri S, Rassenti L, Ghia EM, Widhopf GF, Kipps TJ, Heller MJ. PMID: 24723219; PMCID: PMC4214757.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    166. miR-150 influences B-cell receptor signaling in chronic lymphocytic leukemia by regulating expression of GAB1 and FOXP1. Blood. 2014 Jul 03; 124(1):84-95. Mraz M, Chen L, Rassenti LZ, Ghia EM, Li H, Jepsen K, Smith EN, Messer K, Frazer KA, Kipps TJ. PMID: 24787006; PMCID: PMC4125356.
      View in: PubMed   Mentions: 63     Fields:    Translation:HumansCells
    167. Allele-specific loss and transcription of the miR-15a/16-1 cluster in chronic lymphocytic leukemia. Leukemia. 2015 Jan; 29(1):86-95. Veronese A, Pepe F, Chiacchia J, Pagotto S, Lanuti P, Veschi S, Di Marco M, D'Argenio A, Innocenti I, Vannata B, Autore F, Marchisio M, Wernicke D, Verginelli F, Leone G, Rassenti LZ, Kipps TJ, Mariani-Costantini R, Laurenti L, Croce CM, Visone R. PMID: 24732594; PMCID: PMC4198514.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCells
    168. Repetition in visual word identification: benefits and costs. Q J Exp Psychol (Hove). 2014 Oct; 67(10):1986-2009. Burt JS, Kipps TJ, Matthews JR. PMID: 25248100.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    169. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature. 2014 Feb 20; 506(7488):328-33. Shlush LI, Zandi S, Mitchell A, Chen WC, Brandwein JM, Gupta V, Kennedy JA, Schimmer AD, Schuh AC, Yee KW, McLeod JL, Doedens M, Medeiros JJ, Marke R, Kim HJ, Lee K, McPherson JD, Hudson TJ, HALT Pan-Leukemia Gene Panel Consortium, Brown AM, Yousif F, Trinh QM, Stein LD, Minden MD, Wang JC, Dick JE. PMID: 24522528; PMCID: PMC4991939.
      View in: PubMed   Mentions: 618     Fields:    Translation:HumansAnimalsCells
    170. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014 Mar 13; 370(11):997-1007. Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P, Barrientos JC, Zelenetz AD, Kipps TJ, Flinn I, Ghia P, Eradat H, Ervin T, Lamanna N, Coiffier B, Pettitt AR, Ma S, Stilgenbauer S, Cramer P, Aiello M, Johnson DM, Miller LL, Li D, Jahn TM, Dansey RD, Hallek M, O'Brien SM. PMID: 24450857; PMCID: PMC4161365.
      View in: PubMed   Mentions: 614     Fields:    Translation:HumansCTClinical Trials
    171. Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy. Blood. 2014 Mar 20; 123(12):1810-7. Woyach JA, Smucker K, Smith LL, Lozanski A, Zhong Y, Ruppert AS, Lucas D, Williams K, Zhao W, Rassenti L, Ghia E, Kipps TJ, Mantel R, Jones J, Flynn J, Maddocks K, O'Brien S, Furman RR, James DF, Clow F, Lozanski G, Johnson AJ, Byrd JC. PMID: 24415539; PMCID: PMC3962160.
      View in: PubMed   Mentions: 106     Fields:    Translation:HumansCells
    172. ROR1 can interact with TCL1 and enhance leukemogenesis in Eμ-TCL1 transgenic mice. Proc Natl Acad Sci U S A. 2014 Jan 14; 111(2):793-8. Widhopf GF, Cui B, Ghia EM, Chen L, Messer K, Shen Z, Briggs SP, Croce CM, Kipps TJ. PMID: 24379361; PMCID: PMC3896194.
      View in: PubMed   Mentions: 46     Fields:    Translation:HumansAnimalsCells
    173. Evolution of DNA methylation is linked to genetic aberrations in chronic lymphocytic leukemia. Cancer Discov. 2014 Mar; 4(3):348-61. Oakes CC, Claus R, Gu L, Assenov Y, Hüllein J, Zucknick M, Bieg M, Brocks D, Bogatyrova O, Schmidt CR, Rassenti L, Kipps TJ, Mertens D, Lichter P, Döhner H, Stilgenbauer S, Byrd JC, Zenz T, Plass C. PMID: 24356097; PMCID: PMC4134522.
      View in: PubMed   Mentions: 70     Fields:    Translation:HumansCells
    174. Rapid electrokinetic isolation of cancer-related circulating cell-free DNA directly from blood. Clin Chem. 2014 Mar; 60(3):500-9. Sonnenberg A, Marciniak JY, Rassenti L, Ghia EM, Skowronski EA, Manouchehri S, McCanna J, Widhopf GF, Kipps TJ, Heller MJ. PMID: 24270796; PMCID: PMC4114224.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    175. Chronic lymphocytic leukemia disease progression is accelerated by APRIL-TACI interaction in the TCL1 transgenic mouse model. Blood. 2013 Dec 05; 122(24):3960-3. Lascano V, Guadagnoli M, Schot JG, Luijks DM, Guikema JE, Cameron K, Hahne M, Pals S, Slinger E, Kipps TJ, van Oers MH, Eldering E, Medema JP, Kater AP. PMID: 24100449; PMCID: PMC4123411.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansAnimalsCells
    176. The pathogenesis of chronic lymphocytic leukemia. Annu Rev Pathol. 2014; 9:103-18. Zhang S, Kipps TJ. PMID: 23987584; PMCID: PMC4144790.
      View in: PubMed   Mentions: 44     Fields:    Translation:HumansCells
    177. Stabilized cyclopropane analogs of the splicing inhibitor FD-895. J Med Chem. 2013 Sep 12; 56(17):6576-82. Villa R, Kashyap MK, Kumar D, Kipps TJ, Castro JE, La Clair JJ, Burkart MD. PMID: 23919277; PMCID: PMC3809018.
      View in: PubMed   Mentions: 9     Fields:    Translation:Cells
    178. Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia. Blood. 2013 Sep 12; 122(11):1891-9. Ferrajoli A, Shanafelt TD, Ivan C, Shimizu M, Rabe KG, Nouraee N, Ikuo M, Ghosh AK, Lerner S, Rassenti LZ, Xiao L, Hu J, Reuben JM, Calin S, You MJ, Manning JT, Wierda WG, Estrov Z, O'Brien S, Kipps TJ, Keating MJ, Kay NE, Calin GA. PMID: 23821659; PMCID: PMC3779381.
      View in: PubMed   Mentions: 85     Fields:    Translation:HumansCells
    179. Phase I-II clinical trial of oxaliplatin, fludarabine, cytarabine, and rituximab therapy in aggressive relapsed/refractory chronic lymphocytic leukemia or Richter syndrome. Clin Lymphoma Myeloma Leuk. 2013 Oct; 13(5):568-74. Tsimberidou AM, Wierda WG, Wen S, Plunkett W, O'Brien S, Kipps TJ, Jones JA, Badoux X, Kantarjian H, Keating MJ, Chronic Lymphocytic Leukemia Research Consortium. PMID: 23810245; PMCID: PMC4180513.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCTClinical Trials
    180. IGHV1-69-encoded antibodies expressed in chronic lymphocytic leukemia react with malondialdehyde-acetaldehyde adduct, an immunodominant oxidation-specific epitope. PLoS One. 2013; 8(6):e65203. Que X, Widhopf GF, Amir S, Hartvigsen K, Hansen LF, Woelkers D, Tsimikas S, Binder CJ, Kipps TJ, Witztum JL. PMID: 23840319; PMCID: PMC3688726.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimalsCells
    181. Targeting ROR1 inhibits epithelial-mesenchymal transition and metastasis. Cancer Res. 2013 Jun 15; 73(12):3649-60. Cui B, Zhang S, Chen L, Yu J, Widhopf GF, Fecteau JF, Rassenti LZ, Kipps TJ. PMID: 23771907; PMCID: PMC3832210.
      View in: PubMed   Mentions: 74     Fields:    Translation:HumansAnimalsCells
    182. MicroRNAs and B cell receptor signaling in chronic lymphocytic leukemia. Leuk Lymphoma. 2013 Aug; 54(8):1836-9. Mraz M, Kipps TJ. PMID: 23597135; PMCID: PMC4144718.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansCells
    183. A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma. Haematologica. 2013 Jun; 98(6):964-70. Brown JR, Messmer B, Werner L, Davids MS, Mikler E, Supko JG, Fisher DC, LaCasce AS, Armand P, Jacobsen E, Dalton V, Tesar B, Fernandes SM, McDonough S, Ritz J, Rassenti L, Kipps TJ, Neuberg D, Freedman AS. PMID: 23645694; PMCID: PMC3669454.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCellsCTClinical Trials
    184. Dielectrophoretic isolation and detection of cfc-DNA nanoparticulate biomarkers and virus from blood. Electrophoresis. 2013 Apr; 34(7):1076-84. Sonnenberg A, Marciniak JY, McCanna J, Krishnan R, Rassenti L, Kipps TJ, Heller MJ. PMID: 23436471; PMCID: PMC4517469.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCells
    185. Targeting chronic lymphocytic leukemia cells with a humanized monoclonal antibody specific for CD44. Proc Natl Acad Sci U S A. 2013 Apr 09; 110(15):6127-32. Zhang S, Wu CC, Fecteau JF, Cui B, Chen L, Zhang L, Wu R, Rassenti L, Lao F, Weigand S, Kipps TJ. PMID: 23530247; PMCID: PMC3625269.
      View in: PubMed   Mentions: 36     Fields:    Translation:HumansAnimalsCells
    186. Subclonal evolution involving SF3B1 mutations in chronic lymphocytic leukemia. Leukemia. 2013 Apr; 27(5):1214-7. Schwaederlé M, Ghia E, Rassenti LZ, Obara M, Dell'Aquila ML, Fecteau JF, Kipps TJ. PMID: 23337928; PMCID: PMC3650490.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    187. Impact of oxygen concentration on growth of mesenchymal stromal cells from the marrow of patients with chronic lymphocytic leukemia. Blood. 2013 Feb 07; 121(6):971-4. Fecteau JF, Messmer D, Zhang S, Cui B, Chen L, Kipps TJ. PMID: 23255557; PMCID: PMC3567343.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    188. Heat shock protein 70 regulates Tcl1 expression in leukemia and lymphomas. Blood. 2013 Jan 10; 121(2):351-9. Gaudio E, Paduano F, Ngankeu A, Lovat F, Fabbri M, Sun HL, Gasparini P, Efanov A, Peng Y, Zanesi N, Shuaib MA, Rassenti LZ, Kipps TJ, Li C, Aqeilan RI, Lesinski GB, Trapasso F, Croce CM. PMID: 23160471; PMCID: PMC3544116.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimals
    189. The onco-embryonic antigen ROR1 is expressed by a variety of human cancers. Am J Pathol. 2012 Dec; 181(6):1903-10. Zhang S, Chen L, Wang-Rodriguez J, Zhang L, Cui B, Frankel W, Wu R, Kipps TJ. PMID: 23041612; PMCID: PMC3509760.
      View in: PubMed   Mentions: 87     Fields:    Translation:HumansAnimalsCells
    190. Inhibitors of B-cell receptor signaling for patients with B-cell malignancies. Cancer J. 2012 Sep-Oct; 18(5):404-10. Choi MY, Kipps TJ. PMID: 23006944; PMCID: PMC3461329.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCells
    191. Trisomy 12 CLLs progress through NOTCH1 mutations. Leukemia. 2013 Mar; 27(3):740-3. Balatti V, Lerner S, Rizzotto L, Rassenti LZ, Bottoni A, Palamarchuk A, Cascione L, Alder H, Keating MJ, Kipps TJ, Pekarsky Y, Croce CM. PMID: 22902365; PMCID: PMC3733494.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    192. Increased aldehyde dehydrogenase activity in high-risk chronic lymphocytic leukemia. Leuk Lymphoma. 2013 Feb; 54(2):400-2. Wu RP, Li H, Rassenti LZ, Hayashi T, Wu CN, Kipps TJ, Messer K, Carson DA. PMID: 22784365; PMCID: PMC3821178.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    193. Subnetwork-based analysis of chronic lymphocytic leukemia identifies pathways that associate with disease progression. Blood. 2012 Sep 27; 120(13):2639-49. Chuang HY, Rassenti L, Salcedo M, Licon K, Kohlmann A, Haferlach T, Foà R, Ideker T, Kipps TJ. PMID: 22837534; PMCID: PMC3460686.
      View in: PubMed   Mentions: 40     Fields:    Translation:HumansCells
    194. Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia. J Clin Oncol. 2012 Aug 10; 30(23):2820-2. Cheson BD, Byrd JC, Rai KR, Kay NE, O'Brien SM, Flinn IW, Wiestner A, Kipps TJ. PMID: 22778323; PMCID: PMC3410400.
      View in: PubMed   Mentions: 78     Fields:    Translation:Humans
    195. Single nucleotide polymorphisms and inherited risk of chronic lymphocytic leukemia among African Americans. Blood. 2012 Aug 23; 120(8):1687-90. Coombs CC, Rassenti LZ, Falchi L, Slager SL, Strom SS, Ferrajoli A, Weinberg JB, Kipps TJ, Lanasa MC. PMID: 22745306; PMCID: PMC3429309.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    196. The down-regulation of miR-125b in chronic lymphocytic leukemias leads to metabolic adaptation of cells to a transformed state. Blood. 2012 Sep 27; 120(13):2631-8. Tili E, Michaille JJ, Luo Z, Volinia S, Rassenti LZ, Kipps TJ, Croce CM. PMID: 22723551; PMCID: PMC3460685.
      View in: PubMed   Mentions: 50     Fields:    Translation:HumansCells
    197. Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia. Leuk Lymphoma. 2012 Nov; 53(11):2136-42. Byrd JC, Kipps TJ, Flinn IW, Cooper M, Odenike O, Bendiske J, Rediske J, Bilic S, Dey J, Baeck J, O'Brien S. PMID: 22475052; PMCID: PMC3808981.
      View in: PubMed   Mentions: 40     Fields:    Translation:HumansCTClinical Trials
    198. Quantitative DNA methylation analysis identifies a single CpG dinucleotide important for ZAP-70 expression and predictive of prognosis in chronic lymphocytic leukemia. J Clin Oncol. 2012 Jul 10; 30(20):2483-91. Claus R, Lucas DM, Stilgenbauer S, Ruppert AS, Yu L, Zucknick M, Mertens D, Bühler A, Oakes CC, Larson RA, Kay NE, Jelinek DF, Kipps TJ, Rassenti LZ, Gribben JG, Döhner H, Heerema NA, Marcucci G, Plass C, Byrd JC. PMID: 22564988; PMCID: PMC3397783.
      View in: PubMed   Mentions: 58     Fields:    Translation:HumansCells
    199. Gene immunotherapy of chronic lymphocytic leukemia: a phase I study of intranodally injected adenovirus expressing a chimeric CD154 molecule. Cancer Res. 2012 Jun 15; 72(12):2937-48. Castro JE, Melo-Cardenas J, Urquiza M, Barajas-Gamboa JS, Pakbaz RS, Kipps TJ. PMID: 22505652; PMCID: PMC4114227.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCellsCTClinical Trials
    200. Chronic lymphocytic leukemia associated with immunotactoid glomerulopathy: a case report of successful treatment with high-dose methylprednisolone in combination with rituximab followed by alemtuzumab. Leuk Lymphoma. 2012 Sep; 53(9):1835-8. Castro JE, Diaz-Perez JA, Barajas-Gamboa JS, Horton JM, Weidner N, Kipps TJ. PMID: 22335532; PMCID: PMC4557775.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    201. Intratumoral delivery of CD154 homolog (Ad-ISF35) induces tumor regression: analysis of vector biodistribution, persistence and gene expression. Cancer Gene Ther. 2012 May; 19(5):336-44. Melo-Cardenas J, Urquiza M, Kipps TJ, Castro JE. PMID: 22402624; PMCID: PMC4486070.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimalsCells
    202. ROR1 is expressed in human breast cancer and associated with enhanced tumor-cell growth. PLoS One. 2012; 7(3):e31127. Zhang S, Chen L, Cui B, Chuang HY, Yu J, Wang-Rodriguez J, Tang L, Chen G, Basak GW, Kipps TJ. PMID: 22403610; PMCID: PMC3293865.
      View in: PubMed   Mentions: 123     Fields:    Translation:HumansAnimalsCells
    203. Sorafenib-induced apoptosis of chronic lymphocytic leukemia cells is associated with downregulation of RAF and myeloid cell leukemia sequence 1 (Mcl-1). Mol Med. 2012 Feb 10; 18:19-28. Fecteau JF, Bharati IS, O'Hayre M, Handel TM, Kipps TJ, Messmer D. PMID: 21979753; PMCID: PMC3269641.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCells
    204. Tcl1 protein functions as an inhibitor of de novo DNA methylation in B-cell chronic lymphocytic leukemia (CLL). Proc Natl Acad Sci U S A. 2012 Feb 14; 109(7):2555-60. Palamarchuk A, Yan PS, Zanesi N, Wang L, Rodrigues B, Murphy M, Balatti V, Bottoni A, Nazaryan N, Alder H, Rassenti L, Kipps TJ, Freitas M, Croce CM, Pekarsky Y. PMID: 22308499; PMCID: PMC3289317.
      View in: PubMed   Mentions: 34     Fields:    Translation:HumansCells
    205. Mechanisms and consequences of the loss of PHLPP1 phosphatase in chronic lymphocytic leukemia (CLL). Leukemia. 2012 Jul; 26(7):1689-92. O'Hayre M, Niederst M, Fecteau JF, Nguyen VM, Kipps TJ, Messmer D, Newton AC, Handel TM. PMID: 22237780; PMCID: PMC3395972.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    206. Recombinant antibodies encoded by IGHV1-69 react with pUL32, a phosphoprotein of cytomegalovirus and B-cell superantigen. Blood. 2012 Mar 08; 119(10):2293-301. Steininger C, Widhopf GF, Ghia EM, Morello CS, Vanura K, Sanders R, Spector D, Guiney D, Jäger U, Kipps TJ. PMID: 22234695; PMCID: PMC3311256.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansCells
    207. Structure and function of the hematopoietic cancer niche: focus on chronic lymphocytic leukemia. Front Biosci (Schol Ed). 2012 01 01; 4(1):61-73. Fecteau JF, Kipps TJ. PMID: 22202043; PMCID: PMC4114230.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCells
    208. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol. 2012 Feb 10; 30(5):488-96. Roberts AW, Seymour JF, Brown JR, Wierda WG, Kipps TJ, Khaw SL, Carney DA, He SZ, Huang DC, Xiong H, Cui Y, Busman TA, McKeegan EM, Krivoshik AP, Enschede SH, Humerickhouse R. PMID: 22184378; PMCID: PMC4979082.
      View in: PubMed   Mentions: 349     Fields:    Translation:HumansCTClinical Trials
    209. NOTCH1 mutations in CLL associated with trisomy 12. Blood. 2012 Jan 12; 119(2):329-31. Balatti V, Bottoni A, Palamarchuk A, Alder H, Rassenti LZ, Kipps TJ, Pekarsky Y, Croce CM. PMID: 22086416; PMCID: PMC3257004.
      View in: PubMed   Mentions: 71     Fields:    Translation:HumansCells
    210. Tcl1 interacts with Atm and enhances NF-κB activation in hematologic malignancies. Blood. 2012 Jan 05; 119(1):180-7. Gaudio E, Spizzo R, Paduano F, Luo Z, Efanov A, Palamarchuk A, Leber AS, Kaou M, Zanesi N, Bottoni A, Costinean S, Rassenti LZ, Nakamura T, Kipps TJ, Aqeilan RI, Pekarsky Y, Trapasso F, Croce CM. PMID: 22065599; PMCID: PMC3251228.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansAnimals
    211. ROR1 is expressed on hematogones (non-neoplastic human B-lymphocyte precursors) and a minority of precursor-B acute lymphoblastic leukemia. Leuk Res. 2011 Oct; 35(10):1390-4. Broome HE, Rassenti LZ, Wang HY, Meyer LM, Kipps TJ. PMID: 21813176; PMCID: PMC3163753.
      View in: PubMed   Mentions: 41     Fields:    Translation:HumansCells
    212. Genetic variation in phosphodiesterase (PDE) 7B in chronic lymphocytic leukemia: overview of genetic variants of cyclic nucleotide PDEs in human disease. J Hum Genet. 2011 Sep; 56(9):676-81. Peiró AM, Tang CM, Murray F, Zhang L, Brown LM, Chou D, Rassenti L, Kipps TJ, Kipps TA, Insel PA. PMID: 21796143; PMCID: PMC3833258.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    213. Salinomycin inhibits Wnt signaling and selectively induces apoptosis in chronic lymphocytic leukemia cells. Proc Natl Acad Sci U S A. 2011 Aug 09; 108(32):13253-7. Lu D, Choi MY, Yu J, Castro JE, Kipps TJ, Carson DA. PMID: 21788521; PMCID: PMC3156152.
      View in: PubMed   Mentions: 150     Fields:    Translation:HumansCells
    214. IRF4 mutations in chronic lymphocytic leukemia. Blood. 2011 Sep 08; 118(10):2827-9. Havelange V, Pekarsky Y, Nakamura T, Palamarchuk A, Alder H, Rassenti L, Kipps T, Croce CM. PMID: 21791429; PMCID: PMC3172799.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansCells
    215. Rituximab in chronic lymphocytic leukemia. Adv Ther. 2011 Jul; 28(7):534-54. James DF, Kipps TJ. PMID: 21725721; PMCID: PMC5734916.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    216. miR-181b is a biomarker of disease progression in chronic lymphocytic leukemia. Blood. 2011 Sep 15; 118(11):3072-9. Visone R, Veronese A, Rassenti LZ, Balatti V, Pearl DK, Acunzo M, Volinia S, Taccioli C, Kipps TJ, Croce CM. PMID: 21636858; PMCID: PMC3175784.
      View in: PubMed   Mentions: 60     Fields:    Translation:HumansCells
    217. Autoantibodies against p53 are associated with chromosome 17p deletions in chronic lymphocytic leukemia. Leuk Res. 2011 Jul; 35(7):965-7. Messmer BT, Nour-Omid TS, Ghia E, Sanchez AB, Kipps TJ. PMID: 21570119; PMCID: PMC3116639.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    218. Analyses of recombinant stereotypic IGHV3-21-encoded antibodies expressed in chronic lymphocytic leukemia. J Immunol. 2011 Jun 01; 186(11):6338-44. Ghia EM, Widhopf GF, Rassenti LZ, Kipps TJ. PMID: 21525382; PMCID: PMC7015129.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    219. Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia. Blood. 2011 Jun 16; 117(24):6450-8. Wierda WG, Kipps TJ, Dürig J, Griskevicius L, Stilgenbauer S, Mayer J, Smolej L, Hess G, Griniute R, Hernandez-Ilizaliturri FJ, Padmanabhan S, Gorczyca M, Chang CN, Chan G, Gupta I, Nielsen TG, Russell CA, 407 Study Investigators. PMID: 21498674; PMCID: PMC4916561.
      View in: PubMed   Mentions: 42     Fields:    Translation:HumansCTClinical Trials
    220. Analysis of CLLU1 expression levels before and after therapy in patients with chronic lymphocytic leukemia. Eur J Haematol. 2011 May; 86(5):405-411. Buhl AM, James DF, Neuberg D, Jain S, Rassenti LZ, Kipps TJ. PMID: 21323738; PMCID: PMC4114228.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    221. Laser microdissection for the assessment of the clonal relationship between chronic lymphocytic leukemia/small lymphocytic lymphoma and proliferating B cells within lymph node pseudofollicles. Leukemia. 2011 May; 25(5):883-8. Vandewoestyne ML, Pede VC, Lambein KY, Dhaenens MF, Offner FC, Praet MM, Philippé JJ, Kipps TJ, Deforce DL. PMID: 21321570.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    222. Cyclic nucleotide phosphodiesterase 7B mRNA: an unfavorable characteristic in chronic lymphocytic leukemia. Int J Cancer. 2011 Sep 01; 129(5):1162-9. Zhang L, Murray F, Rassenti LZ, Pu M, Kelly C, Kanter JR, Greaves A, Messer K, Kipps TJ, Insel PA. PMID: 21120911; PMCID: PMC3111850.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    223. Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia. JAMA. 2011 Jan 05; 305(1):59-67. Fabbri M, Bottoni A, Shimizu M, Spizzo R, Nicoloso MS, Rossi S, Barbarotto E, Cimmino A, Adair B, Wojcik SE, Valeri N, Calore F, Sampath D, Fanini F, Vannini I, Musuraca G, Dell'Aquila M, Alder H, Davuluri RV, Rassenti LZ, Negrini M, Nakamura T, Amadori D, Kay NE, Rai KR, Keating MJ, Kipps TJ, Calin GA, Croce CM. PMID: 21205967; PMCID: PMC3690301.
      View in: PubMed   Mentions: 125     Fields:    Translation:HumansCells
    224. Stimulation of chronic lymphocytic leukemia cells with CpG oligodeoxynucleotide gives consistent karyotypic results among laboratories: a CLL Research Consortium (CRC) Study. Cancer Genet Cytogenet. 2010 Dec; 203(2):134-40. Heerema NA, Byrd JC, Dal Cin PS, Dell' Aquila ML, Koduru PR, Aviram A, Smoley SA, Rassenti LZ, Greaves AW, Brown JR, Rai KR, Kipps TJ, Kay NE, Van Dyke DL, Chronic Lymphocytic Leukemia Research Consortium. PMID: 21156225; PMCID: PMC3018693.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCells
    225. Standardization of fluorescence in situ hybridization studies on chronic lymphocytic leukemia (CLL) blood and marrow cells by the CLL Research Consortium. Cancer Genet Cytogenet. 2010 Dec; 203(2):141-8. Smoley SA, Van Dyke DL, Kay NE, Heerema NA, Dell' Aquila ML, Dal Cin P, Koduru P, Aviram A, Rassenti L, Byrd JC, Rai KR, Brown JR, Greaves AW, Eckel-Passow J, Neuberg D, Kipps TJ, Dewald GW. PMID: 21156226; PMCID: PMC3763815.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    226. Progressive but previously untreated CLL patients with greater array CGH complexity exhibit a less durable response to chemoimmunotherapy. Cancer Genet Cytogenet. 2010 Dec; 203(2):161-8. Kay NE, Eckel-Passow JE, Braggio E, Vanwier S, Shanafelt TD, Van Dyke DL, Jelinek DF, Tschumper RC, Kipps T, Byrd JC, Fonseca R. PMID: 21156228; PMCID: PMC3026606.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCells
    227. CCL3 (MIP-1α) plasma levels and the risk for disease progression in chronic lymphocytic leukemia. Blood. 2011 Feb 03; 117(5):1662-9. Sivina M, Hartmann E, Kipps TJ, Rassenti L, Krupnik D, Lerner S, LaPushin R, Xiao L, Huang X, Werner L, Neuberg D, Kantarjian H, O'Brien S, Wierda WG, Keating MJ, Rosenwald A, Burger JA. PMID: 21115978; PMCID: PMC3318778.
      View in: PubMed   Mentions: 61     Fields:    Translation:Humans
    228. Chronic lymphocytic leukemia cells receive RAF-dependent survival signals in response to CXCL12 that are sensitive to inhibition by sorafenib. Blood. 2011 Jan 20; 117(3):882-9. Messmer D, Fecteau JF, O'Hayre M, Bharati IS, Handel TM, Kipps TJ. PMID: 21079155; PMCID: PMC3035080.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCells
    229. B-cell activating factor and v-Myc myelocytomatosis viral oncogene homolog (c-Myc) influence progression of chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2010 Nov 02; 107(44):18956-60. Zhang W, Kater AP, Widhopf GF, Chuang HY, Enzler T, James DF, Poustovoitov M, Tseng PH, Janz S, Hoh C, Herschman H, Karin M, Kipps TJ. PMID: 20956327; PMCID: PMC2973856.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansAnimalsCells
    230. A phase I study of immune gene therapy for patients with CLL using a membrane-stable, humanized CD154. Leukemia. 2010 Nov; 24(11):1893-900. Wierda WG, Castro JE, Aguillon R, Sampath D, Jalayer A, McMannis J, Prussak CE, Keating M, Kipps TJ. PMID: 20882050; PMCID: PMC4556366.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCellsCTClinical Trials
    231. Comparison of familial and sporadic chronic lymphocytic leukaemia using high resolution array comparative genomic hybridization. Br J Haematol. 2010 Nov; 151(4):336-45. Setlur SR, Ihm C, Tchinda J, Shams S, Werner L, Cho EK, Thompson C, Phillips K, Rassenti LZ, Kipps TJ, Neuberg D, Freedman AS, Lee C, Brown JR. PMID: 20812997; PMCID: PMC3584328.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    232. Self-administered, subcutaneous alemtuzumab to treat residual disease in patients with chronic lymphocytic leukemia. Cancer. 2011 Jan 01; 117(1):116-24. Wierda WG, Kipps TJ, Keating MJ, Brown JR, Gribben JG, Browning M, Rassenti LZ, Greaves AW, Neuberg D, O'Brien SM, CLL Research Consortium. PMID: 20806349; PMCID: PMC4535917.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    233. Clinical roundtable monograph. New alternatives in CLL therapy: managing adverse events. Clin Adv Hematol Oncol. 2010 Aug; 8(8):suppl 1-15. Chanan-Khan A, Kipps T, Stilgenbauer S. PMID: 21192630.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    234. Elucidating the CXCL12/CXCR4 signaling network in chronic lymphocytic leukemia through phosphoproteomics analysis. PLoS One. 2010 Jul 22; 5(7):e11716. O'Hayre M, Salanga CL, Kipps TJ, Messmer D, Dorrestein PC, Handel TM. PMID: 20661426; PMCID: PMC2908618.
      View in: PubMed   Mentions: 43     Fields:    Translation:HumansCells
    235. Chronic lymphocytic leukemia modeled in mouse by targeted miR-29 expression. Proc Natl Acad Sci U S A. 2010 Jul 06; 107(27):12210-5. Santanam U, Zanesi N, Efanov A, Costinean S, Palamarchuk A, Hagan JP, Volinia S, Alder H, Rassenti L, Kipps T, Croce CM, Pekarsky Y. PMID: 20566844; PMCID: PMC2901490.
      View in: PubMed   Mentions: 91     Fields:    Translation:HumansAnimalsCells
    236. Reprogramming of miRNA networks in cancer and leukemia. Genome Res. 2010 May; 20(5):589-99. Volinia S, Galasso M, Costinean S, Tagliavini L, Gamberoni G, Drusco A, Marchesini J, Mascellani N, Sana ME, Abu Jarour R, Desponts C, Teitell M, Baffa R, Aqeilan R, Iorio MV, Taccioli C, Garzon R, Di Leva G, Fabbri M, Catozzi M, Previati M, Ambs S, Palumbo T, Garofalo M, Veronese A, Bottoni A, Gasparini P, Harris CC, Visone R, Pekarsky Y, de la Chapelle A, Bloomston M, Dillhoff M, Rassenti LZ, Kipps TJ, Huebner K, Pichiorri F, Lenze D, Cairo S, Buendia MA, Pineau P, Dejean A, Zanesi N, Rossi S, Calin GA, Liu CG, Palatini J, Negrini M, Vecchione A, Rosenberg A, Croce CM. PMID: 20439436; PMCID: PMC2860161.
      View in: PubMed   Mentions: 172     Fields:    Translation:HumansAnimalsCells
    237. Systemic mastocytosis in association with chronic lymphocytic leukemia and plasma cell myeloma. Int J Clin Exp Pathol. 2010 Apr 23; 3(4):448-57. Du S, Rashidi HH, Le DT, Kipps TJ, Broome HE, Wang HY. PMID: 20490336; PMCID: PMC2872752.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    238. Clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of leukemia: report from the International Microarray Innovations in Leukemia Study Group. J Clin Oncol. 2010 May 20; 28(15):2529-37. Haferlach T, Kohlmann A, Wieczorek L, Basso G, Kronnie GT, Béné MC, De Vos J, Hernández JM, Hofmann WK, Mills KI, Gilkes A, Chiaretti S, Shurtleff SA, Kipps TJ, Rassenti LZ, Yeoh AE, Papenhausen PR, Liu WM, Williams PM, Foà R. PMID: 20406941; PMCID: PMC5569671.
      View in: PubMed   Mentions: 285     Fields:    Translation:Humans
    239. microRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival. Blood. 2010 Aug 12; 116(6):945-52. Rossi S, Shimizu M, Barbarotto E, Nicoloso MS, Dimitri F, Sampath D, Fabbri M, Lerner S, Barron LL, Rassenti LZ, Jiang L, Xiao L, Hu J, Secchiero P, Zauli G, Volinia S, Negrini M, Wierda W, Kipps TJ, Plunkett W, Coombes KR, Abruzzo LV, Keating MJ, Calin GA. PMID: 20393129; PMCID: PMC4916575.
      View in: PubMed   Mentions: 92     Fields:    Translation:HumansCells
    240. Chemical biology strategy reveals pathway-selective inhibitor of NF-kappaB activation induced by protein kinase C. ACS Chem Biol. 2010 Mar 19; 5(3):287-99. Shi R, Re D, Dudl E, Cuddy M, Okolotowicz KJ, Dahl R, Su Y, Hurder A, Kitada S, Peddibhotla S, Roth GP, Smith LH, Kipps TJ, Cosford N, Cashman J, Reed JC. PMID: 20141195; PMCID: PMC2842467.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimalsCells
    241. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol. 2010 Apr 01; 28(10):1749-55. Wierda WG, Kipps TJ, Mayer J, Stilgenbauer S, Williams CD, Hellmann A, Robak T, Furman RR, Hillmen P, Trneny M, Dyer MJ, Padmanabhan S, Piotrowska M, Kozak T, Chan G, Davis R, Losic N, Wilms J, Russell CA, Osterborg A, Hx-CD20-406 Study Investigators. PMID: 20194866; PMCID: PMC4979101.
      View in: PubMed   Mentions: 182     Fields:    Translation:HumansCTClinical Trials
    242. A general process for the development of peptide-based immunoassays for monoclonal antibodies. Cancer Chemother Pharmacol. 2010 Oct; 66(5):919-25. Sanchez AB, Nguyen T, Dema-Ala R, Kummel AC, Kipps TJ, Messmer BT. PMID: 20087593; PMCID: PMC2921063.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    243. 13q14 deletions in CLL involve cooperating tumor suppressors. Blood. 2010 May 13; 115(19):3916-22. Palamarchuk A, Efanov A, Nazaryan N, Santanam U, Alder H, Rassenti L, Kipps T, Croce CM, Pekarsky Y. PMID: 20071661; PMCID: PMC2869560.
      View in: PubMed   Mentions: 34     Fields:    Translation:HumansCells
    244. Ethacrynic acid exhibits selective toxicity to chronic lymphocytic leukemia cells by inhibition of the Wnt/beta-catenin pathway. PLoS One. 2009 Dec 14; 4(12):e8294. Lu D, Liu JX, Endo T, Zhou H, Yao S, Willert K, Schmidt-Wolf IG, Kipps TJ, Carson DA. PMID: 20011538; PMCID: PMC2789382.
      View in: PubMed   Mentions: 42     Fields:    Translation:HumansCells
    245. Non-codingRNA sequence variations in human chronic lymphocytic leukemia and colorectal cancer. Carcinogenesis. 2010 Feb; 31(2):208-15. Wojcik SE, Rossi S, Shimizu M, Nicoloso MS, Cimmino A, Alder H, Herlea V, Rassenti LZ, Rai KR, Kipps TJ, Keating MJ, Croce CM, Calin GA. PMID: 19926640; PMCID: PMC2812567.
      View in: PubMed   Mentions: 37     Fields:    Translation:Humans
    246. Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia. Blood. 2010 Jan 21; 115(3):489-95. Byrd JC, Kipps TJ, Flinn IW, Castro J, Lin TS, Wierda W, Heerema N, Woodworth J, Hughes S, Tangri S, Harris S, Wynne D, Molina A, Leigh B, O'Brien S. PMID: 19843887; PMCID: PMC2810983.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCTClinical Trials
    247. Oral fludarabine in untreated patients with B-cell chronic lymphocytic leukemia. Leukemia. 2010 Jan; 24(1):237-9. Shustik C, Turner AR, Desjardins P, Fernandez L, Rubin S, Larratt L, Duncan AM, Rizi D, Sadura A, Shepherd L, Li D, Rassenti L, Kipps T. PMID: 19812607; PMCID: PMC5283722.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    248. Chronic lymphocytic leukemia of Emu-TCL1 transgenic mice undergoes rapid cell turnover that can be offset by extrinsic CD257 to accelerate disease progression. Blood. 2009 Nov 12; 114(20):4469-76. Enzler T, Kater AP, Zhang W, Widhopf GF, Chuang HY, Lee J, Avery E, Croce CM, Karin M, Kipps TJ. PMID: 19755673.
      View in: PubMed   Mentions: 29     Fields:    Translation:Animals
    249. Karyotype-specific microRNA signature in chronic lymphocytic leukemia. Blood. 2009 Oct 29; 114(18):3872-9. Visone R, Rassenti LZ, Veronese A, Taccioli C, Costinean S, Aguda BD, Volinia S, Ferracin M, Palatini J, Balatti V, Alder H, Negrini M, Kipps TJ, Croce CM. PMID: 19717645; PMCID: PMC2773482.
      View in: PubMed   Mentions: 85     Fields:    Translation:HumansCells
    250. Rituximab in combination with high-dose methylprednisolone for the treatment of chronic lymphocytic leukemia. Leukemia. 2009 Oct; 23(10):1779-89. Castro JE, James DF, Sandoval-Sus JD, Jain S, Bole J, Rassenti L, Kipps TJ. PMID: 19693094; PMCID: PMC2761991.
      View in: PubMed   Mentions: 38     Fields:    Translation:Humans
    251. Tumor suppression by phospholipase C-beta3 via SHP-1-mediated dephosphorylation of Stat5. Cancer Cell. 2009 Aug 04; 16(2):161-71. Xiao W, Hong H, Kawakami Y, Kato Y, Wu D, Yasudo H, Kimura A, Kubagawa H, Bertoli LF, Davis RS, Chau LA, Madrenas J, Hsia CC, Xenocostas A, Kipps TJ, Hennighausen L, Iwama A, Nakauchi H, Kawakami T. PMID: 19647226; PMCID: PMC2744338.
      View in: PubMed   Mentions: 39     Fields:    Translation:AnimalsCells
    252. Relative seroprevalence of human herpes viruses in patients with chronic lymphocytic leukaemia. Eur J Clin Invest. 2009 Jun; 39(6):497-506. Steininger C, Rassenti LZ, Vanura K, Eigenberger K, Jäger U, Kipps TJ, Mannhalter C, Stilgenbauer S, Popow-Kraupp T. PMID: 19490058; PMCID: PMC3709071.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    253. The CLLU1 expression level is a stable and inherent feature of the chronic lymphocytic leukemia clone. Leukemia. 2009 Jun; 23(6):1182-6. Buhl AM, Novotny GW, Josefsson P, Nielsen JE, Pedersen LB, Geisler C, Rassenti LZ, Kipps TJ, Jurlander J, Leffers H. PMID: 19212335; PMCID: PMC5283720.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    254. Tcl1 functions as a transcriptional regulator and is directly involved in the pathogenesis of CLL. Proc Natl Acad Sci U S A. 2008 Dec 16; 105(50):19643-8. Pekarsky Y, Palamarchuk A, Maximov V, Efanov A, Nazaryan N, Santanam U, Rassenti L, Kipps T, Croce CM. PMID: 19064921; PMCID: PMC2604915.
      View in: PubMed   Mentions: 53     Fields:    Translation:HumansAnimalsCells
    255. Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens. Blood. 2009 Apr 02; 113(14):3168-71. Lin KI, Tam CS, Keating MJ, Wierda WG, O'Brien S, Lerner S, Coombes KR, Schlette E, Ferrajoli A, Barron LL, Kipps TJ, Rassenti L, Faderl S, Kantarjian H, Abruzzo LV. PMID: 19050308; PMCID: PMC4916943.
      View in: PubMed   Mentions: 36     Fields:    Translation:HumansCTClinical Trials
    256. Cyclic nucleotide phosphodiesterase profiling reveals increased expression of phosphodiesterase 7B in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2008 Dec 09; 105(49):19532-7. Zhang L, Murray F, Zahno A, Kanter JR, Chou D, Suda R, Fenlon M, Rassenti L, Cottam H, Kipps TJ, Insel PA. PMID: 19033455; PMCID: PMC2614795.
      View in: PubMed   Mentions: 46     Fields:    Translation:HumansCells
    257. Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia. Blood. 2009 Jan 08; 113(2):299-305. O'Brien SM, Claxton DF, Crump M, Faderl S, Kipps T, Keating MJ, Viallet J, Cheson BD. PMID: 18931344; PMCID: PMC4968372.
      View in: PubMed   Mentions: 103     Fields:    Translation:HumansCTClinical Trials
    258. An international standardization programme towards the application of gene expression profiling in routine leukaemia diagnostics: the Microarray Innovations in LEukemia study prephase. Br J Haematol. 2008 Sep; 142(5):802-7. Kohlmann A, Kipps TJ, Rassenti LZ, Downing JR, Shurtleff SA, Mills KI, Gilkes AF, Hofmann WK, Basso G, Dell'orto MC, Foà R, Chiaretti S, De Vos J, Rauhut S, Papenhausen PR, Hernández JM, Lumbreras E, Yeoh AE, Koay ES, Li R, Liu WM, Williams PM, Wieczorek L, Haferlach T. PMID: 18573112; PMCID: PMC2654477.
      View in: PubMed   Mentions: 70     Fields:    Translation:Humans
    259. Genomic complexity in chronic lymphocytic leukemia. Blood. 2008 Sep 01; 112(5):1550. Kipps TJ. PMID: 18725569.
      View in: PubMed   Mentions: 1     Fields:    
    260. Rituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocytic leukemia. Leukemia. 2008 Nov; 22(11):2048-53. Castro JE, Sandoval-Sus JD, Bole J, Rassenti L, Kipps TJ. PMID: 18754025; PMCID: PMC5289283.
      View in: PubMed   Mentions: 37     Fields:    Translation:Humans
    261. Chimeric form of tumor necrosis factor-alpha has enhanced surface expression and antitumor activity. Cancer Gene Ther. 2009 Jan; 16(1):53-64. Rieger R, Whitacre D, Cantwell MJ, Prussak C, Kipps TJ. PMID: 18654609; PMCID: PMC7015145.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimalsCells
    262. Computational identification of CDR3 sequence archetypes among immunoglobulin sequences in chronic lymphocytic leukemia. Leuk Res. 2009 Mar; 33(3):368-76. Messmer BT, Raphael BJ, Aerni SJ, Widhopf GF, Rassenti LZ, Gribben JG, Kay NE, Kipps TJ. PMID: 18640719; PMCID: PMC2692898.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    263. Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood. 2008 Sep 01; 112(5):1923-30. Rassenti LZ, Jain S, Keating MJ, Wierda WG, Grever MR, Byrd JC, Kay NE, Brown JR, Gribben JG, Neuberg DS, He F, Greaves AW, Rai KR, Kipps TJ. PMID: 18577710; PMCID: PMC2518894.
      View in: PubMed   Mentions: 117     Fields:    Translation:Humans
    264. MiR-15a and miR-16-1 cluster functions in human leukemia. Proc Natl Acad Sci U S A. 2008 Apr 01; 105(13):5166-71. Calin GA, Cimmino A, Fabbri M, Ferracin M, Wojcik SE, Shimizu M, Taccioli C, Zanesi N, Garzon R, Aqeilan RI, Alder H, Volinia S, Rassenti L, Liu X, Liu CG, Kipps TJ, Negrini M, Croce CM. PMID: 18362358; PMCID: PMC2278188.
      View in: PubMed   Mentions: 317     Fields:    Translation:HumansAnimalsCells
    265. Use of IGHV3-21 in chronic lymphocytic leukemia is associated with high-risk disease and reflects antigen-driven, post-germinal center leukemogenic selection. Blood. 2008 May 15; 111(10):5101-8. Ghia EM, Jain S, Widhopf GF, Rassenti LZ, Keating MJ, Wierda WG, Gribben JG, Brown JR, Rai KR, Byrd JC, Kay NE, Greaves AW, Kipps TJ. PMID: 18326815; PMCID: PMC2384137.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCells
    266. Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a. Proc Natl Acad Sci U S A. 2008 Feb 26; 105(8):3047-52. Fukuda T, Chen L, Endo T, Tang L, Lu D, Castro JE, Widhopf GF, Rassenti LZ, Cantwell MJ, Prussak CE, Carson DA, Kipps TJ. PMID: 18287027; PMCID: PMC2268582.
      View in: PubMed   Mentions: 150     Fields:    Translation:HumansAnimalsCells
    267. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008 Jun 15; 111(12):5446-56. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, Hillmen P, Keating MJ, Montserrat E, Rai KR, Kipps TJ, International Workshop on Chronic Lymphocytic Leukemia. PMID: 18216293; PMCID: PMC2972576.
      View in: PubMed   Mentions: 1101     Fields:    Translation:Humans
    268. Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol. 2008 Jan 10; 26(2):196-203. Tsimberidou AM, Wierda WG, Plunkett W, Kurzrock R, O'Brien S, Wen S, Ferrajoli A, Ravandi-Kashani F, Garcia-Manero G, Estrov Z, Kipps TJ, Brown JR, Fiorentino A, Lerner S, Kantarjian HM, Keating MJ. PMID: 18182662.
      View in: PubMed   Mentions: 44     Fields:    Translation:HumansCTClinical Trials
    269. MicroRNAs in the pathogeny of chronic lymphocytic leukaemia. Br J Haematol. 2007 Dec; 139(5):709-16. Nicoloso MS, Kipps TJ, Croce CM, Calin GA. PMID: 18021085.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansAnimals
    270. ZAP-70 enhances IgM signaling independent of its kinase activity in chronic lymphocytic leukemia. Blood. 2008 Mar 01; 111(5):2685-92. Chen L, Huynh L, Apgar J, Tang L, Rassenti L, Weiss A, Kipps TJ. PMID: 18048647; PMCID: PMC2254551.
      View in: PubMed   Mentions: 66     Fields:    Translation:HumansCells
    271. Value of computed tomography in the monitoring of patients with chronic lymphocytic leukemia. J Clin Oncol. 2007 Dec 10; 25(35):5556. Kipps TJ. PMID: 17984183.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    272. Gene therapy and active immune therapy of hematologic malignancies. Best Pract Res Clin Haematol. 2007 Sep; 20(3):557-68. Wierda WG, Kipps TJ. PMID: 17707840.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    273. The B-cell receptor and ZAP-70 in chronic lymphocytic leukemia. Best Pract Res Clin Haematol. 2007 Sep; 20(3):415-24. Kipps TJ. PMID: 17707830.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCells
    274. Ultraconserved regions encoding ncRNAs are altered in human leukemias and carcinomas. Cancer Cell. 2007 Sep; 12(3):215-29. Calin GA, Liu CG, Ferracin M, Hyslop T, Spizzo R, Sevignani C, Fabbri M, Cimmino A, Lee EJ, Wojcik SE, Shimizu M, Tili E, Rossi S, Taccioli C, Pichiorri F, Liu X, Zupo S, Herlea V, Gramantieri L, Lanza G, Alder H, Rassenti L, Volinia S, Schmittgen TD, Kipps TJ, Negrini M, Croce CM. PMID: 17785203.
      View in: PubMed   Mentions: 344     Fields:    Translation:HumansCells
    275. A high-density SNP genome-wide linkage search of 206 families identifies susceptibility loci for chronic lymphocytic leukemia. Blood. 2007 Nov 01; 110(9):3326-33. Sellick GS, Goldin LR, Wild RW, Slager SL, Ressenti L, Strom SS, Dyer MJ, Mauro FR, Marti GE, Fuller S, Lyttelton M, Kipps TJ, Keating MJ, Call TG, Catovsky D, Caporaso N, Houlston RS. PMID: 17687107; PMCID: PMC2200912.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansCells
    276. Nonstochastic pairing of immunoglobulin heavy and light chains expressed by chronic lymphocytic leukemia B cells is predicated on the heavy chain CDR3. Blood. 2008 Mar 15; 111(6):3137-44. Widhopf GF, Goldberg CJ, Toy TL, Rassenti LZ, Wierda WG, Byrd JC, Keating MJ, Gribben JG, Rai KR, Kipps TJ. PMID: 17675554; PMCID: PMC2265453.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCells
    277. Phase 1 study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measurements in patients with relapsed or refractory chronic lymphocytic leukemia. Clin Cancer Res. 2007 Aug 01; 13(15 Pt 1):4448-55. Byrd JC, O'Brien S, Flinn IW, Kipps TJ, Weiss M, Rai K, Lin TS, Woodworth J, Wynne D, Reid J, Molina A, Leigh B, Harris S. PMID: 17671129.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansCTClinical Trials
    278. Cellular immune therapy for chronic lymphocytic leukemia. Blood. 2007 Oct 15; 110(8):2811-8. Kater AP, van Oers MH, Kipps TJ. PMID: 17638850.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCells
    279. Downregulation of death-associated protein kinase 1 (DAPK1) in chronic lymphocytic leukemia. Cell. 2007 Jun 01; 129(5):879-90. Raval A, Tanner SM, Byrd JC, Angerman EB, Perko JD, Chen SS, Hackanson B, Grever MR, Lucas DM, Matkovic JJ, Lin TS, Kipps TJ, Murray F, Weisenburger D, Sanger W, Lynch J, Watson P, Jansen M, Yoshinaga Y, Rosenquist R, de Jong PJ, Coggill P, Beck S, Lynch H, de la Chapelle A, Plass C. PMID: 17540169; PMCID: PMC4647864.
      View in: PubMed   Mentions: 151     Fields:    Translation:HumansAnimalsCells
    280. International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. Leukemia. 2007 May; 21(5):956-64. Rawstron AC, Villamor N, Ritgen M, Böttcher S, Ghia P, Zehnder JL, Lozanski G, Colomer D, Moreno C, Geuna M, Evans PA, Natkunam Y, Coutre SE, Avery ED, Rassenti LZ, Kipps TJ, Caligaris-Cappio F, Kneba M, Byrd JC, Hallek MJ, Montserrat E, Hillmen P. PMID: 17361231.
      View in: PubMed   Mentions: 102     Fields:    Translation:Humans
    281. Metalloprotease inhibitors block release of soluble CD27 and enhance the immune stimulatory activity of chronic lymphocytic leukemia cells. Exp Hematol. 2007 Mar; 35(3):434-42. Kato K, Chu P, Takahashi S, Hamada H, Kipps TJ. PMID: 17309824.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
    282. Alemtuzumab in chronic lymphocytic leukemia. Future Oncol. 2007 Feb; 3(1):29-42. James DF, Kipps TJ. PMID: 17280499.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    283. Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181. Cancer Res. 2006 Dec 15; 66(24):11590-3. Pekarsky Y, Santanam U, Cimmino A, Palamarchuk A, Efanov A, Maximov V, Volinia S, Alder H, Liu CG, Rassenti L, Calin GA, Hagan JP, Kipps T, Croce CM. PMID: 17178851.
      View in: PubMed   Mentions: 259     Fields:    Translation:HumansCells
    284. Elevation of soluble CD307 (IRTA2/FcRH5) protein in the blood and expression on malignant cells of patients with multiple myeloma, chronic lymphocytic leukemia, and mantle cell lymphoma. Leukemia. 2007 Jan; 21(1):169-74. Ise T, Nagata S, Kreitman RJ, Wilson WH, Wayne AS, Stetler-Stevenson M, Bishop MR, Scheinberg DA, Rassenti L, Kipps TJ, Kyle RA, Jelinek DF, Pastan I. PMID: 17051241.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCells
    285. BAFF and APRIL support chronic lymphocytic leukemia B-cell survival through activation of the canonical NF-kappaB pathway. Blood. 2007 Jan 15; 109(2):703-10. Endo T, Nishio M, Enzler T, Cottam HB, Fukuda T, James DF, Karin M, Kipps TJ. PMID: 16973958; PMCID: PMC1890820.
      View in: PubMed   Mentions: 76     Fields:    Translation:HumansCells
    286. Clinical utility of assessing ZAP-70 and CD38 in chronic lymphocytic leukemia. Cytometry B Clin Cytom. 2006 Jul 15; 70(4):209-13. Rassenti LZ, Kipps TJ. PMID: 16906583.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    287. CD154 induces p73 to overcome the resistance to apoptosis of chronic lymphocytic leukemia cells lacking functional p53. Blood. 2006 Nov 15; 108(10):3450-7. Dicker F, Kater AP, Prada CE, Fukuda T, Castro JE, Sun G, Wang JY, Kipps TJ. PMID: 16741250; PMCID: PMC1895435.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCells
    288. Thymidine-phosphorothioate oligonucleotides induce activation and apoptosis of CLL cells independently of CpG motifs or BCL-2 gene interference. Leukemia. 2006 Apr; 20(4):680-8. Castro JE, Prada CE, Aguillon RA, Kitada S, Fukuda T, Motta M, Wu C, Dicker F, Sun G, Wang JY, Carson DA, Reed JC, Kipps TJ. PMID: 16498393.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    289. CD154 gene therapy for human B-cell malignancies. Ann N Y Acad Sci. 2005 Dec; 1062:51-60. Messmer D, Kipps TJ. PMID: 16461788.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    290. CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood. 2006 Mar 01; 107(5):1761-7. Burger JA, Kipps TJ. PMID: 16269611.
      View in: PubMed   Mentions: 437     Fields:    Translation:HumansAnimalsCells
    291. Flavopiridol administered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activity. Leuk Res. 2005 Nov; 29(11):1253-7. Flinn IW, Byrd JC, Bartlett N, Kipps T, Gribben J, Thomas D, Larson RA, Rai K, Petric R, Ramon-Suerez J, Gabrilove J, Grever MR. PMID: 15916806.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansCTClinical Trials
    292. A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med. 2005 Oct 27; 353(17):1793-801. Calin GA, Ferracin M, Cimmino A, Di Leva G, Shimizu M, Wojcik SE, Iorio MV, Visone R, Sever NI, Fabbri M, Iuliano R, Palumbo T, Pichiorri F, Roldo C, Garzon R, Sevignani C, Rassenti L, Alder H, Volinia S, Liu CG, Kipps TJ, Negrini M, Croce CM. PMID: 16251535.
      View in: PubMed   Mentions: 948     Fields:    Translation:HumansCells
    293. Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemia. Blood. 2006 Feb 01; 107(3):859-61. Binet JL, Caligaris-Cappio F, Catovsky D, Cheson B, Davis T, Dighiero G, Döhner H, Hallek M, Hillmen P, Keating M, Montserrat E, Kipps TJ, Rai K, International Workshop on Chronic Lymphocytic Leukemia (IWCLL). PMID: 16223776.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    294. Increased expression of CD152 (CTLA-4) by normal T lymphocytes in untreated patients with B-cell chronic lymphocytic leukemia. Leukemia. 2005 Oct; 19(10):1788-93. Motta M, Rassenti L, Shelvin BJ, Lerner S, Kipps TJ, Keating MJ, Wierda WG. PMID: 16094420.
      View in: PubMed   Mentions: 36     Fields:    Translation:HumansCells
    295. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A. 2005 Sep 27; 102(39):13944-9. Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M, Wojcik SE, Aqeilan RI, Zupo S, Dono M, Rassenti L, Alder H, Volinia S, Liu CG, Kipps TJ, Negrini M, Croce CM. PMID: 16166262; PMCID: PMC1236577.
      View in: PubMed   Mentions: 1440     Fields:    Translation:HumansCells
    296. Novel immune-based treatment strategies for chronic lymphocytic leukemia. J Clin Oncol. 2005 Sep 10; 23(26):6325-32. Wierda WG, Kipps TJ, Keating MJ. PMID: 16155015.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    297. Treatment of solid tumors with immunotoxins. Breast Cancer Res. 2005; 7(5):184-6. Messmer D, Kipps TJ. PMID: 16168135; PMCID: PMC1242142.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    298. ZAP-70 is a novel conditional heat shock protein 90 (Hsp90) client: inhibition of Hsp90 leads to ZAP-70 degradation, apoptosis, and impaired signaling in chronic lymphocytic leukemia. Blood. 2005 Oct 01; 106(7):2506-12. Castro JE, Prada CE, Loria O, Kamal A, Chen L, Burrows FJ, Kipps TJ. PMID: 15972449; PMCID: PMC1895276.
      View in: PubMed   Mentions: 39     Fields:    Translation:HumansCells
    299. Inhibitors of XIAP sensitize CD40-activated chronic lymphocytic leukemia cells to CD95-mediated apoptosis. Blood. 2005 Sep 01; 106(5):1742-8. Kater AP, Dicker F, Mangiola M, Welsh K, Houghten R, Ostresh J, Nefzi A, Reed JC, Pinilla C, Kipps TJ. PMID: 15914559; PMCID: PMC1895220.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCells
    300. Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells. Blood. 2005 Sep 01; 106(5):1824-30. Burger M, Hartmann T, Krome M, Rawluk J, Tamamura H, Fujii N, Kipps TJ, Burger JA. PMID: 15905192.
      View in: PubMed   Mentions: 102     Fields:    Translation:HumansCells
    301. Nurselike cells express BAFF and APRIL, which can promote survival of chronic lymphocytic leukemia cells via a paracrine pathway distinct from that of SDF-1alpha. Blood. 2005 Aug 01; 106(3):1012-20. Nishio M, Endo T, Tsukada N, Ohata J, Kitada S, Reed JC, Zvaifler NJ, Kipps TJ. PMID: 15860672; PMCID: PMC1895149.
      View in: PubMed   Mentions: 97     Fields:    Translation:HumansCells
    302. Familial cancer associated with a polymorphism in ARLTS1. N Engl J Med. 2005 Apr 21; 352(16):1667-76. Calin GA, Trapasso F, Shimizu M, Dumitru CD, Yendamuri S, Godwin AK, Ferracin M, Bernardi G, Chatterjee D, Baldassarre G, Rattan S, Alder H, Mabuchi H, Shiraishi T, Hansen LL, Overgaard J, Herlea V, Mauro FR, Dighiero G, Movsas B, Rassenti L, Kipps T, Baffa R, Fusco A, Mori M, Russo G, Liu CG, Neuberg D, Bullrich F, Negrini M, Croce CM. PMID: 15843669.
      View in: PubMed   Mentions: 37     Fields:    Translation:HumansAnimalsCells
    303. TWIST2 demonstrates differential methylation in immunoglobulin variable heavy chain mutated and unmutated chronic lymphocytic leukemia. J Clin Oncol. 2005 Jun 10; 23(17):3877-85. Raval A, Lucas DM, Matkovic JJ, Bennett KL, Liyanarachchi S, Young DC, Rassenti L, Kipps TJ, Grever MR, Byrd JC, Plass C. PMID: 15809452.
      View in: PubMed   Mentions: 39     Fields:    Translation:HumansCells
    304. Chronic lymphocytic leukemia cells display p53-dependent drug-induced Puma upregulation. Leukemia. 2005 Mar; 19(3):427-34. Mackus WJ, Kater AP, Grummels A, Evers LM, Hooijbrink B, Kramer MH, Castro JE, Kipps TJ, van Lier RA, van Oers MH, Eldering E. PMID: 15674362.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCells
    305. Fibroblast-like synoviocytes of mesenchymal origin express functional B cell-activating factor of the TNF family in response to proinflammatory cytokines. J Immunol. 2005 Jan 15; 174(2):864-70. Ohata J, Zvaifler NJ, Nishio M, Boyle DL, Kalled SL, Carson DA, Kipps TJ. PMID: 15634908.
      View in: PubMed   Mentions: 48     Fields:    Translation:HumansCells
    306. ZAP-70 directly enhances IgM signaling in chronic lymphocytic leukemia. Blood. 2005 Mar 01; 105(5):2036-41. Chen L, Apgar J, Huynh L, Dicker F, Giago-McGahan T, Rassenti L, Weiss A, Kipps TJ. PMID: 15514014.
      View in: PubMed   Mentions: 57     Fields:    Translation:HumansCells
    307. Free circulating soluble CD52 as a tumor marker in chronic lymphocytic leukemia and its implication in therapy with anti-CD52 antibodies. Cancer. 2004 Sep 01; 101(5):999-1008. Albitar M, Do KA, Johnson MM, Giles FJ, Jilani I, O'Brien S, Cortes J, Thomas D, Rassenti LZ, Kipps TJ, Kantarjian HM, Keating M. PMID: 15329909.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCells
    308. Fas-ligand (CD178) and TRAIL synergistically induce apoptosis of CD40-activated chronic lymphocytic leukemia B cells. Blood. 2005 Apr 15; 105(8):3193-8. Dicker F, Kater AP, Fukuda T, Kipps TJ. PMID: 15339846.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansAnimalsCells
    309. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med. 2004 Aug 26; 351(9):893-901. Rassenti LZ, Huynh L, Toy TL, Chen L, Keating MJ, Gribben JG, Neuberg DS, Flinn IW, Rai KR, Byrd JC, Kay NE, Greaves A, Weiss A, Kipps TJ. PMID: 15329427.
      View in: PubMed   Mentions: 254     Fields:    Translation:HumansCells
    310. MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci U S A. 2004 Aug 10; 101(32):11755-60. Calin GA, Liu CG, Sevignani C, Ferracin M, Felli N, Dumitru CD, Shimizu M, Cimmino A, Zupo S, Dono M, Dell'Aquila ML, Alder H, Rassenti L, Kipps TJ, Bullrich F, Negrini M, Croce CM. PMID: 15284443; PMCID: PMC511048.
      View in: PubMed   Mentions: 463     Fields:    Translation:HumansCells
    311. Chronic lymphocytic leukemia B cells of more than 1% of patients express virtually identical immunoglobulins. Blood. 2004 Oct 15; 104(8):2499-504. Widhopf GF, Rassenti LZ, Toy TL, Gribben JG, Wierda WG, Kipps TJ. PMID: 15217828.
      View in: PubMed   Mentions: 75     Fields:    Translation:HumansCells
    312. Rational design and real time, in-cell detection of the proapoptotic activity of a novel compound targeting Bcl-X(L). Chem Biol. 2004 Mar; 11(3):389-95. Becattini B, Kitada S, Leone M, Monosov E, Chandler S, Zhai D, Kipps TJ, Reed JC, Pellecchia M. PMID: 15123268.
      View in: PubMed   Mentions: 41     Fields:    Translation:HumansCells
    313. Activation of the Wnt signaling pathway in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2004 Mar 02; 101(9):3118-23. Lu D, Zhao Y, Tawatao R, Cottam HB, Sen M, Leoni LM, Kipps TJ, Corr M, Carson DA. PMID: 14973184; PMCID: PMC365753.
      View in: PubMed   Mentions: 153     Fields:    Translation:HumansCells
    314. Transgenic expression of a human polyreactive Ig expressed in chronic lymphocytic leukemia generates memory-type B cells that respond to nonspecific immune activation. J Immunol. 2004 Feb 15; 172(4):2092-9. Widhopf GF, Brinson DC, Kipps TJ, Tighe H. PMID: 14764674.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimalsCells
    315. Retraction: The triterpenoid CDDO-Imidazolide induces apoptosis and enhances fludarabine-induced apoptosis of CLL B-cells. Blood. 2004 Aug 15; 104(4):932. Pedersen IM, Zapata JM, Samuel T, Scott FL, Salvesen GS, Honda T, Gribble GW, Suh N, Sporn MB, Kipps TJ, Reed JC. PMID: 14739219.
      View in: PubMed   Mentions:    Fields:    
    316. Functional expression of CXCR4 (CD184) on small-cell lung cancer cells mediates migration, integrin activation, and adhesion to stromal cells. Oncogene. 2003 Nov 06; 22(50):8093-101. Burger M, Glodek A, Hartmann T, Schmitt-Gräff A, Silberstein LE, Fujii N, Kipps TJ, Burger JA. PMID: 14603250.
      View in: PubMed   Mentions: 86     Fields:    Translation:HumansAnimalsCells
    317. CpG oligodeoxynucleotides enhance the capacity of adenovirus-mediated CD154 gene transfer to generate effective B-cell lymphoma vaccines. Cancer Res. 2003 Jul 15; 63(14):4128-35. Rieger R, Kipps TJ. PMID: 12874017.
      View in: PubMed   Mentions: 7     Fields:    Translation:AnimalsCells
    318. Immunobiology of chronic lymphocytic leukemia. Curr Opin Hematol. 2003 Jul; 10(4):312-8. Kipps TJ. PMID: 12799538.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    319. Selection of oligonucleotide aptamers with enhanced uptake and activation of human leukemia B cells. Hum Gene Ther. 2003 Jun 10; 14(9):849-60. Wu CC, Castro JE, Motta M, Cottam HB, Kyburz D, Kipps TJ, Corr M, Carson DA. PMID: 12828856.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansAnimalsCells
    320. In vivo activation of signal transducer and activator of transcription 1 after CD154 gene therapy for chronic lymphocytic leukemia is associated with clinical and immunologic response. Clin Cancer Res. 2003 Jun; 9(6):2166-72. Battle TE, Wierda WG, Rassenti LZ, Zahrieh D, Neuberg D, Kipps TJ, Frank DA. PMID: 12796382.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    321. CRC Tissue Core Management System (TCMS): integration of basic science and clinical data for translational research. AMIA Annu Symp Proc. 2003; 853. Greaves AW, Payne PR, Rassenti L, Kipps TJ. PMID: 14728358; PMCID: PMC1480018.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    322. Biology and treatment of chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2003; 153-75. Keating MJ, Chiorazzi N, Messmer B, Damle RN, Allen SL, Rai KR, Ferrarini M, Kipps TJ. PMID: 14633781.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansAnimals
    323. CRC Clinical Trials Management System (CTMS): an integrated information management solution for collaborative clinical research. AMIA Annu Symp Proc. 2003; 967. Payne PR, Greaves AW, Kipps TJ. PMID: 14728471; PMCID: PMC1480351.
      View in: PubMed   Mentions: 7     Fields:    
    324. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2002 Nov 26; 99(24):15524-9. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, Aldler H, Rattan S, Keating M, Rai K, Rassenti L, Kipps T, Negrini M, Bullrich F, Croce CM. PMID: 12434020; PMCID: PMC137750.
      View in: PubMed   Mentions: 1893     Fields:    Translation:HumansCells
    325. The triterpenoid CDDO induces apoptosis in refractory CLL B cells. Blood. 2002 Oct 15; 100(8):2965-72. Pedersen IM, Kitada S, Schimmer A, Kim Y, Zapata JM, Charboneau L, Rassenti L, Andreeff M, Bennett F, Sporn MB, Liotta LD, Kipps TJ, Reed JC. PMID: 12351409.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansCells
    326. HSV amplicon-mediated delivery of LIGHT enhances the antigen-presenting capacity of chronic lymphocytic leukemia. Mol Ther. 2002 Oct; 6(4):455-63. Tolba KA, Bowers WJ, Eling DJ, Casey AE, Kipps TJ, Federoff HJ, Rosenblatt JD. PMID: 12377186.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    327. Protection of CLL B cells by a follicular dendritic cell line is dependent on induction of Mcl-1. Blood. 2002 Sep 01; 100(5):1795-801. Pedersen IM, Kitada S, Leoni LM, Zapata JM, Karras JG, Tsukada N, Kipps TJ, Choi YS, Bennett F, Reed JC. PMID: 12176902.
      View in: PubMed   Mentions: 78     Fields:    Translation:HumansCells
    328. Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. Blood. 2002 Dec 15; 100(13):4609-14. Chen L, Widhopf G, Huynh L, Rassenti L, Rai KR, Weiss A, Kipps TJ. PMID: 12393534.
      View in: PubMed   Mentions: 133     Fields:    Translation:HumansCells
    329. Immune and cell therapy of hematologic malignancies. Int J Hematol. 2002 Aug; 76 Suppl 1:269-73. Kipps TJ. PMID: 12430862.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    330. Adenovirus transduction to effect CD40 signalling improves the immune stimulatory activity of myeloma cells. Br J Haematol. 2002 Aug; 118(2):506-13. Bashey A, Cantwell MJ, Kipps TJ. PMID: 12139739.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    331. Latent sensitivity to Fas-mediated apoptosis after CD40 ligation may explain activity of CD154 gene therapy in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2002 Mar 19; 99(6):3854-9. Chu P, Deforce D, Pedersen IM, Kim Y, Kitada S, Reed JC, Kipps TJ. PMID: 11891278; PMCID: PMC122613.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansAnimalsCells
    332. Chemokine receptors and stromal cells in the homing and homeostasis of chronic lymphocytic leukemia B cells. Leuk Lymphoma. 2002 Mar; 43(3):461-6. Burger JA, Kipps TJ. PMID: 12002747.
      View in: PubMed   Mentions: 50     Fields:    Translation:HumansCells
    333. Distinctive features of "nurselike" cells that differentiate in the context of chronic lymphocytic leukemia. Blood. 2002 Feb 01; 99(3):1030-7. Tsukada N, Burger JA, Zvaifler NJ, Kipps TJ. PMID: 11807009.
      View in: PubMed   Mentions: 86     Fields:    Translation:HumansCells
    334. Advances in classification and therapy of indolent B-cell malignancies. Semin Oncol. 2002 Feb; 29(1 Suppl 2):98-104. Kipps TJ. PMID: 11842396.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    335. Advances in classification and therapy of indolent B-cell malignancies. Semin Oncol. 2002 Feb; 29(1S2):98-104. Kipps TJ. PMID: 28140099.
      View in: PubMed   Mentions: 2     Fields:    
    336. Sequential modulation of growth factors: a novel strategy for adoptive immunotherapy of acute myeloid leukemia. Biol Blood Marrow Transplant. 2002; 8(10):557-68. Zhong RK, Rassenti LZ, Kipps TJ, Chen J, Law P, Yu JF, Ball ED. PMID: 12434951.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    337. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med. 2001 Dec 03; 194(11):1639-47. Rosenwald A, Alizadeh AA, Widhopf G, Simon R, Davis RE, Yu X, Yang L, Pickeral OK, Rassenti LZ, Powell J, Botstein D, Byrd JC, Grever MR, Cheson BD, Chiorazzi N, Wilson WH, Kipps TJ, Brown PO, Staudt LM. PMID: 11733578; PMCID: PMC2193523.
      View in: PubMed   Mentions: 266     Fields:    Translation:Humans
    338. Soluble CD154 in rheumatoid arthritis: elevated plasma levels in cases with vasculitis. J Rheumatol. 2001 Dec; 28(12):2583-90. Tamura N, Kobayashi S, Kato K, Bando H, Haruta K, Oyanagi M, Kuriyama M, Kipps TJ, Hashimoto H. PMID: 11764201.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    339. Biochemical genetic analysis of indanocine resistance in human leukemia. Cancer Res. 2001 Oct 01; 61(19):7248-54. Hua XH, Genini D, Gussio R, Tawatao R, Shih H, Kipps TJ, Carson DA, Leoni LM. PMID: 11585762.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    340. Characterization of the 13q14 tumor suppressor locus in CLL: identification of ALT1, an alternative splice variant of the LEU2 gene. Cancer Res. 2001 Sep 15; 61(18):6640-8. Bullrich F, Fujii H, Calin G, Mabuchi H, Negrini M, Pekarsky Y, Rassenti L, Alder H, Reed JC, Keating MJ, Kipps TJ, Croce CM. PMID: 11559527.
      View in: PubMed   Mentions: 55     Fields:    Translation:HumansAnimalsCells
    341. T cell activation following infection of primary follicle center lymphoma B cells with adenovirus encoding CD154. Leukemia. 2001 Sep; 15(9):1451-7. Cantwell MJ, Wierda WG, Lossos IS, Levy R, Kipps TJ. PMID: 11516107.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimalsCells
    342. Cloning and characterization of CLLD6, CLLD7, and CLLD8, novel candidate genes for leukemogenesis at chromosome 13q14, a region commonly deleted in B-cell chronic lymphocytic leukemia. Cancer Res. 2001 Apr 01; 61(7):2870-7. Mabuchi H, Fujii H, Calin G, Alder H, Negrini M, Rassenti L, Kipps TJ, Bullrich F, Croce CM. PMID: 11306461.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansCells
    343. Plasmids encoding granulocyte-macrophage colony-stimulating factor and CD154 enhance the immune response to genetic vaccines. Vaccine. 2001 Feb 28; 19(15-16):2181-9. Burger JA, Mendoza RB, Kipps TJ. PMID: 11228391.
      View in: PubMed   Mentions: 7     Fields:    Translation:AnimalsCells
    344. Fibroblast-like synoviocytes support B-cell pseudoemperipolesis via a stromal cell-derived factor-1- and CD106 (VCAM-1)-dependent mechanism. J Clin Invest. 2001 Feb; 107(3):305-15. Burger JA, Zvaifler NJ, Tsukada N, Firestein GS, Kipps TJ. PMID: 11160154; PMCID: PMC199194.
      View in: PubMed   Mentions: 50     Fields:    Translation:HumansCells
    345. Normal B cells express 51p1-encoded Ig heavy chains that are distinct from those expressed by chronic lymphocytic leukemia B cells. J Immunol. 2001 Jan 01; 166(1):95-102. Widhopf GF, Kipps TJ. PMID: 11123281.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCells
    346. Immunogenetic therapy for B-cell malignancies. Semin Oncol. 2000 Dec; 27(6 Suppl 12):104-9. Kipps TJ, Chu P, Wierda WG. PMID: 11225994.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    347. TNFR-associated factor family protein expression in normal tissues and lymphoid malignancies. J Immunol. 2000 Nov 01; 165(9):5084-96. Zapata JM, Krajewska M, Krajewski S, Kitada S, Welsh K, Monks A, McCloskey N, Gordon J, Kipps TJ, Gascoyne RD, Shabaik A, Reed JC. PMID: 11046039.
      View in: PubMed   Mentions: 49     Fields:    Translation:HumansAnimalsCells
    348. CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia. Blood. 2000 Nov 01; 96(9):2917-24. Wierda WG, Cantwell MJ, Woods SJ, Rassenti LZ, Prussak CE, Kipps TJ. PMID: 11049967.
      View in: PubMed   Mentions: 76     Fields:    Translation:HumansCellsCTClinical Trials
    349. Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood. 2000 Oct 15; 96(8):2655-63. Burger JA, Tsukada N, Burger M, Zvaifler NJ, Dell'Aquila M, Kipps TJ. PMID: 11023495.
      View in: PubMed   Mentions: 271     Fields:    Translation:HumansCells
    350. Gene therapy of hematologic malignancies. Semin Oncol. 2000 Oct; 27(5):502-11. Wierda WG, Kipps TJ. PMID: 11049018.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    351. Cytotoxicity, apoptosis, and viral replication in tumor cells treated with oncolytic ribonucleotide reductase-defective herpes simplex type 1 virus (hrR3) combined with ionizing radiation. Cancer Gene Ther. 2000 Jul; 7(7):1051-9. Spear MA, Sun F, Eling DJ, Gilpin E, Kipps TJ, Chiocca EA, Bouvet M. PMID: 10917208.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    352. Chronic lymphocytic leukemia B cells are highly sensitive to infection by herpes simplex virus-1 via herpesvirus-entry-mediator A. Gene Ther. 2000 Jul; 7(14):1210-6. Eling DJ, Johnson PA, Sharma S, Tufaro F, Kipps TJ. PMID: 10918489.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimalsCells
    353. Chronic lymphocytic leukemia. Curr Opin Hematol. 2000 Jul; 7(4):223-34. Kipps TJ. PMID: 10882178.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCells
    354. CD40 activation does not protect chronic lymphocytic leukemia B cells from apoptosis induced by cytotoxic T lymphocytes. Blood. 2000 Jun 15; 95(12):3853-8. Chu P, Wierda WG, Kipps TJ. PMID: 10845920.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    355. Genetics of chronic lymphocytic leukaemia. Hematol Cell Ther. 2000 Jun; 42(1):5-14. Kipps TJ. PMID: 11036944.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    356. Expression of Ig-beta (CD79b) by chronic lymphocytic leukemia B cells that lack immunoglobulin heavy-chain allelic exclusion. Blood. 2000 Apr 15; 95(8):2725-7. Rassenti LZ, Kipps TJ. PMID: 10753858.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    357. Local and systemic effects after adenoviral transfer of the murine granulocyte-macrophage colony-stimulating factor gene into mice. Br J Haematol. 2000 Mar; 108(3):641-52. Burger JA, Baird SM, Powell HC, Sharma S, Eling DJ, Kipps TJ. PMID: 10759724.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimalsCells
    358. Limitations of in vivo IL-12 supplementation strategies to induce Th1 early life responses to model viral and bacterial vaccine antigens. Virology. 2000 Mar 01; 268(1):122-31. Kovarik J, Martinez X, Pihlgren M, Bozzotti P, Tao MH, Kipps TJ, Wild TF, Lambert PH, Siegrist CA. PMID: 10683334.
      View in: PubMed   Mentions: 8     Fields:    Translation:AnimalsCellsPHPublic Health
    359. Genetic engineering strategies for hematologic malignancies. Genet Eng (N Y). 2000; 22:197-207. Kipps TJ. PMID: 11501377.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    360. Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells. Blood. 1999 Dec 01; 94(11):3658-67. Burger JA, Burger M, Kipps TJ. PMID: 10572077.
      View in: PubMed   Mentions: 173     Fields:    Translation:HumansCells
    361. Future strategies toward the cure of indolent B-cell malignancies. Molecular genetic approaches. Semin Hematol. 1999 Oct; 36(4 Suppl 5):3-8. Kipps TJ. PMID: 10528909.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    362. The soluble CD40 ligand sCD154 in systemic lupus erythematosus. J Clin Invest. 1999 Oct; 104(7):947-55. Kato K, Santana-Sahagún E, Rassenti LZ, Weisman MH, Tamura N, Kobayashi S, Hashimoto H, Kipps TJ. PMID: 10510335; PMCID: PMC408556.
      View in: PubMed   Mentions: 50     Fields:    Translation:HumansCells
    363. Reduction in mitochondrial membrane potential is an early event in Fas-independent CTL-mediated apoptosis. Cell Immunol. 1999 Jul 10; 195(1):43-52. Hu D, Kipps TJ. PMID: 10433796.
      View in: PubMed   Mentions: 9     Fields:    Translation:AnimalsCells
    364. Chronic lymphocytic leukemia. Curr Opin Hematol. 1999 Jul; 6(4):253-61. Wierda WG, Kipps TJ. PMID: 10400375.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    365. Extending genetic vaccines with chemokines. Nat Biotechnol. 1999 Mar; 17(3):226-7. Kipps T, Mendoza R. PMID: 10096284.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    366. ATM mutations in B-cell chronic lymphocytic leukemia. Cancer Res. 1999 Jan 01; 59(1):24-7. Bullrich F, Rasio D, Kitada S, Starostik P, Kipps T, Keating M, Albitar M, Reed JC, Croce CM. PMID: 9892178.
      View in: PubMed   Mentions: 43     Fields:    Translation:HumansCells
    367. Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. J Clin Invest. 1998 Oct 15; 102(8):1515-25. Fais F, Ghiotto F, Hashimoto S, Sellars B, Valetto A, Allen SL, Schulman P, Vinciguerra VP, Rai K, Rassenti LZ, Kipps TJ, Dighiero G, Schroeder HW, Ferrarini M, Chiorazzi N. PMID: 9788964; PMCID: PMC509001.
      View in: PubMed   Mentions: 228     Fields:    Translation:HumansCells
    368. Aberrant and unstable expression of immunoglobulin genes in persons infected with human immunodeficiency virus. Blood. 1998 Aug 15; 92(4):1317-23. Bessudo A, Rassenti L, Havlir D, Richman D, Feigal E, Kipps TJ. PMID: 9694720.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    369. Chronic lymphocytic leukemia. Curr Opin Hematol. 1998 Jul; 5(4):244-53. Kipps TJ. PMID: 9747630.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimals
    370. DNA vaccines encoding full-length or truncated Neu induce protective immunity against Neu-expressing mammary tumors. Cancer Res. 1998 May 01; 58(9):1965-71. Chen Y, Hu D, Eling DJ, Robbins J, Kipps TJ. PMID: 9581840.
      View in: PubMed   Mentions: 14     Fields:    Translation:AnimalsCells
    371. Gene transfer of CD40-ligand induces autologous immune recognition of chronic lymphocytic leukemia B cells. J Clin Invest. 1998 Mar 01; 101(5):1133-41. Kato K, Cantwell MJ, Sharma S, Kipps TJ. PMID: 9486984; PMCID: PMC508665.
      View in: PubMed   Mentions: 42     Fields:    Translation:HumansCells
    372. Immunostimulatory effects of a plasmid expressing CD40 ligand (CD154) on gene immunization. J Immunol. 1997 Dec 15; 159(12):5777-81. Mendoza RB, Cantwell MJ, Kipps TJ. PMID: 9550372.
      View in: PubMed   Mentions: 21     Fields:    Translation:AnimalsCells
    373. Deoxyribonucleic acid vaccines encoding antigens with rapid proteasome-dependent degradation are highly efficient inducers of cytolytic T lymphocytes. J Immunol. 1997 Dec 15; 159(12):6037-43. Wu Y, Kipps TJ. PMID: 9550402.
      View in: PubMed   Mentions: 18     Fields:    Translation:AnimalsCells
    374. Signal transduction pathways and mechanisms of apoptosis in CLL B-lymphocytes: their role in CLL pathogenesis. Hematol Cell Ther. 1997 Nov; 39 Suppl 1:S17-27. Kipps TJ. PMID: 9471058.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    375. Deficient Fas ligand expression by synovial lymphocytes from patients with rheumatoid arthritis. Arthritis Rheum. 1997 Sep; 40(9):1644-52. Cantwell MJ, Hua T, Zvaifler NJ, Kipps TJ. PMID: 9324019.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    376. Acquired CD40-ligand deficiency in chronic lymphocytic leukemia. Nat Med. 1997 Sep; 3(9):984-9. Cantwell M, Hua T, Pappas J, Kipps TJ. PMID: 9288724.
      View in: PubMed   Mentions: 42     Fields:    Translation:HumansCells
    377. Chronic lymphocytic leukemia. Curr Opin Hematol. 1997 Jul; 4(4):268-76. Kipps TJ. PMID: 9260055.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    378. Lack of allelic exclusion in B cell chronic lymphocytic leukemia. J Exp Med. 1997 Apr 21; 185(8):1435-45. Rassenti LZ, Kipps TJ. PMID: 9126924; PMCID: PMC2196272.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCells
    379. Expression of an Ig VH gene, 51p1, is proportional to its germline gene copy number. Ann N Y Acad Sci. 1997 Apr 05; 815:478-80. Sasso EH, Johnson T, Kipps TJ. PMID: 9186703.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimalsCells
    380. Human B cell biology. Int Rev Immunol. 1997; 15(3-4):243-64. Kipps TJ. PMID: 9222821.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    381. Ig VH1 genes expressed in B cell chronic lymphocytic leukemia exhibit distinctive molecular features. J Immunol. 1997 Jan 01; 158(1):235-46. Johnson TA, Rassenti LZ, Kipps TJ. PMID: 8977195.
      View in: PubMed   Mentions: 47     Fields:    Translation:HumansCells
    382. The human immunoglobulin V(H) gene repertoire is genetically controlled and unaltered by chronic autoimmune stimulation. J Clin Invest. 1996 Dec 15; 98(12):2794-800. Kohsaka H, Carson DA, Rassenti LZ, Ollier WE, Chen PP, Kipps TJ, Miyasaka N. PMID: 8981926; PMCID: PMC507745.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    383. Adenovirus vector infection of chronic lymphocytic leukemia B cells. Blood. 1996 Dec 15; 88(12):4676-83. Cantwell MJ, Sharma S, Friedmann T, Kipps TJ. PMID: 8977261.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCells
    384. Identification of a promoter element that regulates tissue-specific expression of the human CD80 (B7.1) gene. J Immunol. 1996 Nov 15; 157(10):4442-50. Fong TC, Wu Y, Kipps TJ. PMID: 8906820.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    385. Efficient infection of a human T-cell line and of human primary peripheral blood leukocytes with a pseudotyped retrovirus vector. Proc Natl Acad Sci U S A. 1996 Oct 15; 93(21):11842-7. Sharma S, Cantwell M, Kipps TJ, Friedmann T. PMID: 8876225; PMCID: PMC38146.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansAnimalsCells
    386. What is the CLL B-lymphocyte? Leuk Lymphoma. 1996 Oct; 22 Suppl 2:13-39. Dighiero G, Kipps T, Schroeder HW, Chiorazzi N, Stevenson F, Silberstein LE, Caligaris-Cappio F, Ferrarini M. PMID: 9021706.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    387. Favored use of immunoglobulin V(H)4 Genes in AIDS-associated B-cell lymphoma. Blood. 1996 Jul 01; 88(1):252-60. Bessudo A, Cherepakhin V, Johnson TA, Rassenti LZ, Feigal E, Kipps TJ. PMID: 8704181.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    388. Expression of the immunoglobulin VH gene 51p1 is proportional to its germline gene copy number. J Clin Invest. 1996 May 01; 97(9):2074-80. Sasso EH, Johnson T, Kipps TJ. PMID: 8621797; PMCID: PMC507282.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansCells
    389. The V4-34 encoded anti-i autoantibodies recognize a large subset of human and mouse B-cells. Blood Cells Mol Dis. 1996; 22(2):126-38. Silberstein LE, George A, Durdik JM, Kipps TJ. PMID: 8931953.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansAnimalsCells
    390. Analysis of immunoglobulin VH gene repertoire by an anchored PCR-ELISA. Ann N Y Acad Sci. 1995 Sep 29; 764:463-73. Rassenti LZ, Kohsaka H, Kipps TJ. PMID: 7486567.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    391. Origin of high-grade lymphomas in Richter syndrome. Leuk Lymphoma. 1995 Aug; 18(5-6):367-72. Bessudo A, Kipps TJ. PMID: 8528042.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    392. Expression of CD27 and its ligand, CD70, on chronic lymphocytic leukemia B cells. Blood. 1995 Jun 15; 85(12):3556-65. Ranheim EA, Cantwell MJ, Kipps TJ. PMID: 7540066.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansCells
    393. Tumor necrosis factor-alpha facilitates induction of CD80 (B7-1) and CD54 on human B cells by activated T cells: complex regulation by IL-4, IL-10, and CD40L. Cell Immunol. 1995 Apr 01; 161(2):226-35. Ranheim EA, Kipps TJ. PMID: 7535196.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCells
    394. Anti-B cell autoantibodies encoded by VH 4-21 genes in human fetal spleen do not require in vivo somatic selection. Eur J Immunol. 1994 Dec; 24(12):2941-9. Parr TB, Johnson TA, Silberstein LE, Kipps TJ. PMID: 7805720.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    395. Elevated expression of CD80 (B7/BB1) and other accessory molecules on synovial fluid mononuclear cell subsets in rheumatoid arthritis. Arthritis Rheum. 1994 Nov; 37(11):1637-46. Ranheim EA, Kipps TJ. PMID: 7526869.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCells
    396. X inactivation and immunocompetence in female carriers of the X-linked hyper-IgM syndrome. J Clin Invest. 1994 Aug; 94(2):469. Kipps TJ. PMID: 8040297; PMCID: PMC295103.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    397. Structure-function studies on a polyreactive (natural) autoantibody. Polyreactivity is dependent on somatically generated sequences in the third complementarity-determining region of the antibody heavy chain. J Immunol. 1994 Jun 15; 152(12):5988-96. Martin T, Crouzier R, Weber JC, Kipps TJ, Pasquali JL. PMID: 8207223.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansAnimalsCells
    398. Transforming growth factor beta as endogenous growth inhibitor of chronic lymphocytic leukemia B cells. J Exp Med. 1994 Mar 01; 179(3):999-1004. Lotz M, Ranheim E, Kipps TJ. PMID: 8113691; PMCID: PMC2191408.
      View in: PubMed   Mentions: 45     Fields:    Translation:HumansAnimalsCells
    399. Autoantigen inhibits apoptosis of a human B cell leukemia that produces pathogenic rheumatoid factor. J Immunol. 1993 Dec 15; 151(12):7273-83. Kobayashi R, Rassenti LZ, Meisenholder G, Carson DA, Kipps TJ. PMID: 7505024.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    400. Common clonal origin of chronic lymphocytic leukemia and high-grade lymphoma of Richter's syndrome. Blood. 1993 Nov 15; 82(10):3141-7. Cherepakhin V, Baird SM, Meisenholder GW, Kipps TJ. PMID: 7693038.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    401. Immunoglobulin VH3 gene products: natural ligands for HIV gp120. Science. 1993 Sep 17; 261(5128):1588-91. Berberian L, Goodglick L, Kipps TJ, Braun J. PMID: 7690497.
      View in: PubMed   Mentions: 85     Fields:    Translation:HumansCells
    402. Induction of antibodies to a kappa V region by gene immunization. J Immunol. 1993 Sep 01; 151(5):2871-6. Watanabe A, Raz E, Kohsaka H, Tighe H, Baird SM, Kipps TJ, Carson DA. PMID: 8360497.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    403. Systemic immunological effects of cytokine genes injected into skeletal muscle. Proc Natl Acad Sci U S A. 1993 May 15; 90(10):4523-7. Raz E, Watanabe A, Baird SM, Eisenberg RA, Parr TB, Lotz M, Kipps TJ, Carson DA. PMID: 8506293; PMCID: PMC46544.
      View in: PubMed   Mentions: 19     Fields:    Translation:Animals
    404. Autoantibodies in chronic lymphocytic leukemia and related systemic autoimmune diseases. Blood. 1993 May 15; 81(10):2475-87. Kipps TJ, Carson DA. PMID: 8490163.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCells
    405. Lack of extensive mutations in the VH5 genes used in common B cell chronic lymphocytic leukemia. J Exp Med. 1993 Apr 01; 177(4):1039-46. Rassenti LZ, Kipps TJ. PMID: 7681468; PMCID: PMC2190987.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCells
    406. Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal. J Exp Med. 1993 Apr 01; 177(4):925-35. Ranheim EA, Kipps TJ. PMID: 7681471; PMCID: PMC2190967.
      View in: PubMed   Mentions: 120     Fields:    Translation:HumansAnimalsCells
    407. Relationship of deoxycytidine kinase and cytoplasmic 5'-nucleotidase to the chemotherapeutic efficacy of 2-chlorodeoxyadenosine. Blood. 1993 Feb 01; 81(3):597-601. Kawasaki H, Carrera CJ, Piro LD, Saven A, Kipps TJ, Carson DA. PMID: 8094016.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansCells
    408. Function of B cells expressing a human immunoglobulin M rheumatoid factor autoantibody in transgenic mice. J Exp Med. 1993 Jan 01; 177(1):109-18. Tighe H, Chen PP, Tucker R, Kipps TJ, Roudier J, Jirik FR, Carson DA. PMID: 8418195; PMCID: PMC2190869.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansAnimalsCells
    409. Gene therapy for cancer. J Hematother. 1993; 2(3):367-72. Kipps TJ. PMID: 7921998.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    410. Immunoglobulin genes in chronic lymphocytic leukemia. Blood Cells. 1993; 19(3):615-25; discussion 631-2. Kipps TJ. PMID: 8018942.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCells
    411. Epstein-Barr virus-induced human B-cell lymphomas in SCID mice reconstituted with human peripheral blood leukocytes. Cancer Res. 1992 Oct 01; 52(19 Suppl):5552s-5553s. Mosier DE, Picchio GR, Baird SM, Kobayashi R, Kipps TJ. PMID: 1327510.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansAnimalsCells
    412. Transfer of human chronic lymphocytic leukemia to mice with severe combined immune deficiency. Leuk Res. 1992 Oct; 16(10):1013-23. Kobayashi R, Picchio G, Kirven M, Meisenholder G, Baird S, Carson DA, Mosier DE, Kipps TJ. PMID: 1383641.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimalsCells
    413. An anti-B cell autoantibody from Wiskott-Aldrich syndrome which recognizes i blood group specificity on normal human B cells. Eur J Immunol. 1992 Jul; 22(7):1781-8. Grillot-Courvalin C, Brouet JC, Piller F, Rassenti LZ, Labaume S, Silverman GJ, Silberstein L, Kipps TJ. PMID: 1623923.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCells
    414. New developments in flow cytometric analyses of lymphocyte markers. Clin Lab Med. 1992 Jun; 12(2):237-75. Kipps TJ, Meisenholder G, Robbins BA. PMID: 1611820.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    415. Immunoglobulin V gene expression in CD5 B-cell malignancies. Ann N Y Acad Sci. 1992 May 04; 651:373-83. Kipps TJ, Rassenti LZ, Duffy S, Johnson T, Kobayashi R, Carson DA. PMID: 1376056.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimalsCells
    416. EBV-induced human B cell lymphomas in hu-PBL-SCID mice. AIDS Res Hum Retroviruses. 1992 May; 8(5):735-40. Mosier DE, Picchio GR, Kirven MB, Garnier JL, Torbett BE, Baird SM, Kobayashi R, Kipps TJ. PMID: 1325170.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimalsCells
    417. Heterogeneity among Epstein-Barr virus-seropositive donors in the generation of immunoblastic B-cell lymphomas in SCID mice receiving human peripheral blood leukocyte grafts. Cancer Res. 1992 May 01; 52(9):2468-77. Picchio GR, Kobayashi R, Kirven M, Baird SM, Kipps TJ, Mosier DE. PMID: 1314693.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansAnimalsCells
    418. Evidence for somatic selection of natural autoantibodies. J Exp Med. 1992 Apr 01; 175(4):983-91. Martin T, Duffy SF, Carson DA, Kipps TJ. PMID: 1552291; PMCID: PMC2119194.
      View in: PubMed   Mentions: 38     Fields:    Translation:AnimalsCells
    419. Oral antilymphocyte activity and induction of apoptosis by 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine. Proc Natl Acad Sci U S A. 1992 Apr 01; 89(7):2970-4. Carson DA, Wasson DB, Esparza LM, Carrera CJ, Kipps TJ, Cottam HB. PMID: 1348362; PMCID: PMC48785.
      View in: PubMed   Mentions: 32     Fields:    Translation:AnimalsCells
    420. Molecular characterization of a supratypic cross-reactive idiotype associated with IgM autoantibodies. J Immunol. 1991 Sep 15; 147(6):2041-6. Pratt LF, Szubin R, Carson DA, Kipps TJ. PMID: 1890310.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    421. Autoantibody-encoding kappa L chain genes frequently rearranged in lambda L chain-expressing chronic lymphocytic leukemia. J Immunol. 1991 Aug 01; 147(3):1060-6. Rassenti LZ, Pratt LF, Chen PP, Carson DA, Kipps TJ. PMID: 1907304.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    422. Relationship of the CD5 B cell to human tonsillar lymphocytes that express autoantibody-associated cross-reactive idiotypes. J Clin Invest. 1991 Jun; 87(6):2087-96. Kipps TJ, Duffy SF. PMID: 1710233; PMCID: PMC296965.
      View in: PubMed   Mentions: 20     Fields:    Translation:Cells
    423. Idiotypic cross-reactivity of immunoglobulins expressed in Waldenström's macroglobulinemia, chronic lymphocytic leukemia, and mantle zone lymphocytes of secondary B-cell follicles. Blood. 1991 Apr 01; 77(7):1484-90. Axelrod O, Silverman GJ, Dev V, Kyle R, Carson DA, Kipps TJ. PMID: 1901234.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    424. New roles for rheumatoid factor. J Clin Invest. 1991 Feb; 87(2):379-83. Carson DA, Chen PP, Kipps TJ. PMID: 1991824; PMCID: PMC295087.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansCells
    425. Immunoglobulin gene expression in systemic rheumatic diseases. Br J Rheumatol. 1991; 30 Suppl 1:43-6. Carson DA, Chen PP, Silverman GJ, Kipps TJ. PMID: 1991239.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimals
    426. Immunoglobulin Gene Rearrangement and Expression in B-CLL. Leuk Lymphoma. 1991; 5 Suppl 1:39-45. Kipps TJ, Rassenti LZ, Duffy S, Kobayashi R, Martin T, Chen PP, Carson DA. PMID: 27463478.
      View in: PubMed   Mentions:    Fields:    
    427. CD5-positive B-cell malignancies frequently express cross-reactive idiotypes associated with IgM autoantibodies. Am J Pathol. 1990 Apr; 136(4):809-16. Kipps TJ, Robbins BA, Tefferi A, Meisenholder G, Banks PM, Carson DA. PMID: 1691593; PMCID: PMC1877648.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
    428. Intraclonal diversity in the VH genes expressed by CD5- chronic lymphocytic leukemia-producing pathologic IgM rheumatoid factor. J Immunol. 1990 Feb 15; 144(4):1526-30. Roudier J, Silverman GJ, Chen PP, Carson DA, Kipps TJ. PMID: 1689356.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCells
    429. Preferential linkage of bcl-2 to immunoglobulin light chain gene in chronic lymphocytic leukemia. J Exp Med. 1990 Feb 01; 171(2):559-64. Adachi M, Tefferi A, Greipp PR, Kipps TJ, Tsujimoto Y. PMID: 2106002; PMCID: PMC2187727.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansCells
    430. Immunoglobulin idiotypes in human B cell neoplasia. Implications for pathogenesis and therapy. Chem Immunol. 1990; 48:167-84. Kipps TJ. PMID: 2403805.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    431. EBV-associated B-cell lymphomas following transfer of human peripheral blood lymphocytes to mice with severe combined immune deficiency. Curr Top Microbiol Immunol. 1990; 166:317-23. Mosier DE, Baird SM, Kirven MB, Gulizia RJ, Wilson DB, Kubayashi R, Picchio G, Garnier JL, Sullivan JL, Kipps TJ. PMID: 1963581.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansAnimalsCells
    432. Uniform high frequency expression of autoantibody-associated crossreactive idiotypes in the primary B cell follicles of human fetal spleen. J Exp Med. 1990 Jan 01; 171(1):189-96. Kipps TJ, Robbins BA, Carson DA. PMID: 1688607; PMCID: PMC2187670.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCells
    433. Regulation of rheumatoid factor synthesis. Clin Exp Rheumatol. 1989 Sep-Oct; 7 Suppl 3:S69-73. Carson DA, Chen PP, Kipps TJ, Roudier J, Silverman GJ, Tighe H. PMID: 2691162.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    434. Developmentally restricted immunoglobulin heavy chain variable region gene expressed at high frequency in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 1989 Aug; 86(15):5913-7. Kipps TJ, Tomhave E, Pratt LF, Duffy S, Chen PP, Carson DA. PMID: 2503826; PMCID: PMC297741.